

Modeling neurodevelopmental disorder-associated *hAGO1* mutations in *C. elegans* Argonaute *ALG-1*.

Ye Duan^{1,2,6}, Li Li^{3,6}, Ganesh Prabhakar Panzade³, Amélie Piton⁴, Anna Zinovyeva^{3,5}, Victor Ambros^{1,5}

1. Program of Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01605.
2. Department of Organismic and Evolutionary Biology, Museum of Comparative Zoology, Harvard University, Cambridge, MA, 02138.
3. Division of Biology, Kansas State University, Manhattan, KS, 66506
4. Institute of Genetics and Molecular and Cellular Biology, Strasbourg University, CNRS UMR7104, INSERM U1258, Illkirch, France
5. Lead contact
6. These authors contributed equally.

Correspondence: zinovyeva@ksu.edu (A.Z.) victor.ambros@umassmed.edu (V.A.)

1 **ABSTRACT**

2 MicroRNAs (miRNA) are endogenous non-coding RNAs important for post-transcriptional
3 regulation of gene expression. miRNAs associate with Argonaute proteins to bind to the 3' UTR
4 of target genes and confer target repression. Recently, multiple *de novo* coding variants in the
5 human Argonaute gene *AGO1* (*hAGO1*) have been reported to cause a neurodevelopmental
6 disorder (NDD) with intellectual disability (ID). Most of the altered amino acids are conserved
7 between the miRNA-associated Argonautes in *H. sapiens* and *C. elegans*, suggesting the *hAGO1*
8 mutations could disrupt evolutionarily conserved functions in the miRNA pathway. To investigate
9 how the *hAGO1* mutations may affect miRNA biogenesis and/or functions, we genetically
10 modeled four of the *hAGO1 de novo* variants (referred to as NDD mutations) by introducing the
11 identical mutations to the *C. elegans hAGO1 homolog, alg-1*. This array of mutations caused
12 distinct effects on *C. elegans* miRNA functions, miRNA populations, and downstream gene
13 expression, indicative of profound alterations in aspects of miRNA processing and miRISC
14 formation and/or activity. Specifically, we found that the *alg-1* NDD mutations cause allele-specific
15 disruptions in mature miRNA profiles both in terms of overall abundances and association with
16 mutant ALG-1. We also observed allele-specific profiles of gene expression with altered
17 translational efficiency and/or mRNA abundance. The sets of perturbed genes include human
18 homologs whose dysfunction is known to cause NDD. We anticipate that these cross-clade
19 genetic studies may advance the understanding of fundamental Argonaute functions and provide
20 insights into the conservation of miRNA-mediated post-transcriptional regulatory mechanisms.

21

22 **Key words:** microRNA, Argonaute, neurodevelopmental defect, intellectual disability, *C.*
23 *elegans*, *hAGO1*, *alg-1*, disease modeling

24 INTRODUCTION

25 The proper development, maintenance, and physiological functioning of multicellular
26 organisms require the robust control of complex and dynamic patterns of gene expression.
27 MicroRNAs (miRNAs) are endogenous, small, non-coding RNAs that play important roles in post-
28 transcriptional regulation of gene expression in essentially all developmental and physiological
29 contexts [1-3]. miRNAs are transcribed from miRNA-encoding genomic loci and undergo several
30 processing steps to functional maturation. The initial primary miRNA (pri-miRNA) transcript is
31 processed within the nucleus by the Microprocessor into the precursor miRNA (pre-miRNA) [2,
32 4]. The pre-miRNA is further processed in the cytoplasm by Dicer into the RNA duplex, which
33 associates with a dedicated miRNA co-factor protein of the Argonaute (AGO) family. One miRNA
34 strand from the duplex is retained by the Argonaute and becomes the functional miRNA, while
35 the other strand is expelled from the complex and degraded. The most frequently loaded miRNA
36 strand from the duplex is defined as the guide miRNA (miR), while the typically disposed strand
37 is defined as the passenger (miR*). The miRNA-Argonaute complex subsequently recruits other
38 protein factors including GW182 to form the miRNA-induced silencing complex (miRISC) [2]. In
39 general, miRISC binds target messenger RNAs (mRNAs) at sites within in the 3' untranslated
40 region (3' UTR) via partially complementary base-pairing between the miRNA and the mRNA
41 target [2]. miRISC binding then leads to translational inhibition and/or mRNA destabilization,
42 resulting in repression of the target gene product expression [5].

43 As key miRNA co-factors, the Argonaute (AGO) proteins are essential for miRNA-
44 mediated post-transcriptional gene regulation [6, 7]. The AGO proteins participate in multiple
45 steps of miRNA biogenesis and function, including pre-miRNA processing, miRNA duplex loading,
46 strand selection, passenger strand disposal, target mRNA recognition, and repression of target
47 gene expression. Accordingly, depleting AGOs by mutation or RNAi can result in global defects
48 in miRNA biogenesis and target repression, and consequently lead to phenotypes characteristic
49 of miRNA *loss-of-function* [7-11].

50 Interestingly, certain point mutations at conserved residues of *C. elegans* miRNA-
51 associated Argonaute ALG-1 cause heterochronic developmental phenotypes without significant
52 disruption of ALG-1 protein levels nor elimination of the capacity of the mutant ALG-1 protein to
53 associate with miRNAs [12]. Strikingly, these mutants, referred to as the *alg-1* antimorphic
54 mutants, exhibit more severe developmental defects than *alg-1 null* mutants do. Current evidence
55 suggests that in the *alg-1 null* mutant, the loss of *alg-1* functions is largely compensated by the
56 paralogous *alg-2* gene, whose protein product ALG-2 associates with the miRNAs that would

57 ordinarily bind ALG-1 [7]. However, in the *alg-1* antimorphic mutants, the mutant ALG-1
58 antagonizes the redundancy of *alg-2* by sequestering miRNAs in defective ALG-1 miRISC,
59 preventing those miRNAs from associating with ALG-2 [12].

60 AGO genes are implicated in multiple human diseases including male infertility, colon
61 cancer, ovarian cancer, gastric cancer, gliomas, and neuronal developmental disorder (NDD) [13-
62 17]. In certain cases, the disease is associated with loss of function of multiple members of the
63 AGO family: Five children with psychomotor developmental delay and other non-specific
64 neuronal-muscular disorder syndromes have been reported to be heterozygous for large *de novo*
65 deletions in the *1p34.3* locus, which includes *hAGO1*, *hAGO3*, and *hAGO4* [18, 19]. Other cases
66 involve *de novo* point mutations that change or delete a single amino acid of one AGO locus:
67 Exome sequencing identified 18 *de novo* coding variants of *hAGO1* in children who exhibit NDD
68 with intellectual disability (ID) and autism-spectrum disorder (ASD) [20]; similarly, 12 *de novo*
69 coding variants of *hAGO2* were identified in children with similar spectrums of developmental
70 delay, ID, and ASD symptoms [21]. In several cases, the same *de novo* mutations have been
71 identified in independent families, reinforcing the conclusion that the corresponding amino acids
72 critically contribute to AGO function. Many of the mutated amino acids are conserved between
73 *hAGO1* and *hAGO2*, as well as between the homologous human and *C. elegans* AGO genes
74 (Figure 1A). The conservation of these amino acids and the phenotypes associated with the
75 corresponding mutants suggest that these amino acids are critical for evolutionarily conserved
76 functions of AGO proteins.

77 It is noteworthy that among the described NDD cases, frameshift mutations or large
78 deletions that could result in unambiguous single-gene *null* mutations of *hAGO1* or *hAGO2* were
79 rarely documented [22]. This suggests that the NDD-associated single amino acid mutations of
80 *hAGO1* or *hAGO2* may be more malicious than either *null* allele, perhaps by antagonizing
81 otherwise redundant paralogous AGO genes. Interestingly, two of the NDD-related *de novo*
82 mutations (corresponding to H751L and C749Y in *hAGO1*) are adjacent to the previously
83 described antimorphic allele (corresponding to S750F in *hAGO1*) in *C. elegans alg-1* (Figure 1A)
84 [12]. Thus, it is likely that some of the NDD-related AGO mutations may have antimorphic impact
85 on AGO function. We thus reasoned that modeling the NDD-related human AGO mutations in
86 conserved *C. elegans* AGO mutations could provide a rapid way to assess the effects of the
87 mutation on miRNA biogenesis and miRNA/AGO functionality.

88 Here, we reproduced four *hAGO1* mutations (F180 Δ , G199S, V254I, H751L) in the
89 homologous *C. elegans alg-1* gene using CRISPR/Cas9-mediated genome editing. We refer to

90 the corresponding *C. elegans* mutations as *alg-1* NDD mutations. We show that the *alg-1* NDD
91 mutations resulted in developmental phenotypes ranging from loss-of-function to antimorphic,
92 with two *alg-1* NDD mutations resulting in stronger heterochronic phenotypes than the
93 homozygous *alg-1 null* mutants. The antimorphic character of *alg-1* NDD mutations suggests that
94 the mutant ALG-1 protein interferes or competes with the functions of paralogous Argonaute
95 proteins (nominally ALG-2 in *C. elegans*). We found that *alg-1* NDD mutations affected the overall
96 profile of mature miRNAs and the profile of miRNAs associated with ALG-1 protein, including the
97 proper selection of mature miRNA guide/passenger strands. We also observed that the mutations
98 caused global gene expression perturbations in terms of both mRNA levels and mRNA
99 translational status, including substantial differences in the de-repression modes of miRNA
100 targets for certain mutations. Interestingly, the set of *alg-1* NDD mutations examined here exhibit
101 distinguishable allele-specific perturbations in *C. elegans* miRNA function, miRNA profiles, and
102 gene expression, suggesting that the NDD mutations each impair ALG-1 functionality with allele-
103 specificity. Lastly, we show that a large proportion of the genes whose expression is perturbed by
104 the *alg-1* NDD mutations are known to have human homologs whose dysfunction is known to
105 cause NDD. Our results demonstrate that modeling *hAGO1* mutations in a *C. elegans* Argonaute
106 can advance the understanding of fundamental Argonaute functions and provide insights into the
107 conservation of miRNA-mediated regulatory mechanisms.

108

109 **RESULTS**

110 **The NDD mutations disrupt ALG-1 Argonaute function.**

111 We selected four *hAGO1* NDD-related mutations (F180 Δ , G199S, V254I, H751L) to model
112 in *C. elegans* ALG-1. All four mutations had been identified in multiple patients, with the F180 Δ ,
113 G199S, and V254I mutations identified in independent families [20]. Further, the F180 Δ and
114 G199S mutations were also identified at homologous positions of *hAGO2*, causing NDD with ID
115 and ASD symptoms [21]. The amino acids mutated in *hAGO1* (F180, G199, V254, H751) are
116 conserved among the four miRNA-associated AGO proteins in humans (*hAGO1-hAGO4*), as well
117 as their two *C. elegans* orthologs, ALG-1 and ALG-2 (Figure 1A). The mutated F180 and G199
118 amino acids reside in the L1 hinge domain, which lies between the MID-PIWI lobe and the PAZ-
119 N lobe (Figure 1B-C). The V254 amino acid resides in the PAZ domain with the side-chain
120 exposed to the surface of AGO1 protein and is distant from the PAZ-N channel where the 3' non-

121 seed duplex is located (Figure 1B-C). The H751 amino acid resides in the PIWI domain and is
122 near the MID-PIWI channel where the miRNA seed duplexes with the target (Figure 1B, 2A).

123 To explore how the NDD mutations may affect the functionality of miRNA regulation, we
124 used CRISPR/Cas9 genome editing to generate four *C. elegans* mutant strains, each containing
125 a mutation identical to F180Δ, G199S, V254I, or H751L at the corresponding amino acids of *C.*
126 *elegans* ALG-1. Note that in this paper, we refer to each *C. elegans* ALG-1 mutation using the
127 human *AGO1* addresses of the corresponding amino acid (Figure 1A). The respective *C. elegans*
128 mutants are *alg-1(ma447, F180Δ)*, *alg-1(ma443, G199S)*, *alg-1(zen25, V254I)* and *alg-1(zen18,*
129 *H751L)*.

130 *C. elegans* animals homozygous for each of the four *alg-1* NDD mutations exhibit varying
131 degrees of developmental defects (Figure 1D-H). *alg-1(F180Δ)* and *alg-1(H751L)* hermaphrodites
132 exhibit strong adult lethality (Figure 1D), caused by impaired egg laying (retention of embryos and
133 eventual matricide by the progeny that hatch *in utero*) and/or rupturing of the cuticle at the vulva,
134 which kills the adult outright before reproduction. Both these phenotypes are presumed to reflect
135 defective vulval development owing to decreased activity of certain miRNAs known to be critical
136 for normal vulva development [7]. In accordance with their underlying egg retention and/or vulva
137 bursting defects, *alg-1* NDD mutant hermaphrodites produced a dramatically reduced number of
138 progeny (Figure 1E). The penetrance of the adult lethality and reduced progeny phenotypes for
139 the H751L and F180Δ mutants were at least as strong as for *alg-1(tm492, null)* mutants (Figure
140 1D-E). *alg-1(G199S)* animals exhibited moderate penetrance of vulval defects and reduced
141 number of progeny, and *alg-1(V254I)* mutants exhibited relatively mild and temperature-
142 dependent expression of these phenotypes (Figure 1D-E). Thus, based on phenotypic
143 comparison with *alg-1 null*, we conclude that the F180Δ, G199S, V254I, and H751L mutations
144 cause varying degrees of ALG-1 loss-of-function [7, 12].

145

146 **The *alg-1* NDD mutations synergize with the *alg-2 null*.**

147 Functional redundancy has been reported among miRNA-related *AGO* genes, both for the
148 human Ago family (*hAGO1-hAGO4*) and for the *C. elegans* *alg-1* and *alg-2* [7, 12, 23]. To test for
149 redundancy associated with the functions disrupted by the *alg-1* NDD mutations, we crossed each
150 of the four *alg-1* mutations into the *alg-2(ok304, null)* genetic background. We found that the *alg-*
151 *1(F180Δ); alg-2(null)* and *alg-1(H751); alg-2(null)* mutants exhibited embryonic lethality,
152 consistent with severe reduction of both *alg-1* and *alg-2* functions [7] (Figure 1F). Meanwhile, the

153 weaker *alg-1* NDD mutations also exhibited genetic interactions with *alg-2 null* mutation: *alg-*
154 *1(G199S)*; *alg-2(null)* mutants showed increased adult lethality and reduced number of progeny
155 compared to *alg-1(G199S)* and *alg-1(V254I)*; *alg-2(null)* animals exhibited increased adult lethality
156 compared to *alg-1(V254I)* (Figure 1F). Since both the vulva developmental defect and the
157 reduction in the progeny of all four *alg-1* NDD mutations were exacerbated in the *alg-2 null*
158 background, we conclude that the *alg-1* NDD mutations disrupt, to varying degrees, *alg-1*
159 functions that are redundant with *alg-2*.

160

161 ***alg-1(F180Δ)* and *alg-1(H751L)* mutations are antimorphic in regulating seam cell**
162 **differentiation.**

163 In *C. elegans*, lateral hypodermal development involves a stem cell lineage wherein the
164 stem cells (seam cells) execute asymmetric divisions at each larval stage, producing one
165 daughter cell that differentiates and joins the hypodermal syncytium (Hyp7) and another daughter
166 cell that remains a stem cell [24]. At the final larval molt, seam cells cease division, and all
167 hypodermal cells (seam and Hyp7) express the adult-specific hypodermal gene *col-19* [25, 26].
168 miRNAs – particularly the *lin-4* family and *let-7* family miRNAs -- are critical for controlling the
169 timing of this larval-to-adult hypodermal cell fate transition [3, 27, 28]. Accordingly, mutations that
170 disrupt these miRNAs or the miRNA machinery can cause the failure of hypodermal cells to
171 properly express adult fates, as reported by the expression of the *col-19::gfp* transgene, including
172 reduced or absent *col-19::gfp* expression in Hyp7 [12, 29] (Figure 1G).

173 We found that *alg-1(F180Δ)*, *alg-1(H751L)*, and *alg-1(G199S)* adults exhibited reduced or
174 absent *col-19::gfp* expression in Hyp7 cells, indicating that the NDD mutations impair
175 heterochronic pathway miRNA activity (Figure 1H). Strikingly, the heterochronic phenotypes of
176 the *alg-1(H751)* (80.7%) and *alg-1(F180Δ)* (76.6%) were significantly stronger than that of the
177 *alg-1(null)* mutant (38.6%) (Figure 1H). Since *alg-1(H751L)* and *alg-1(F180Δ)* homozygotes
178 exhibit phenotypes stronger than *alg-1(null)* homozygotes, we conclude that the *alg-1(F180Δ)*
179 and *alg-1(H751L)* mutations are antimorphic and that these mutations do not simply inactivate
180 the ALG-1 protein, but alter ALG-1 function such that the mutant protein inappropriately interferes
181 with the function of other gene products – in this case presumably ALG-2. The antimorphic
182 behavior of the *alg-1(F180Δ)* and *alg-1(H751L)* mutations is reminiscent of other *C. elegans alg-*
183 *1* alleles that were identified in forward screens for heterochronic mutants and are likewise point
184 mutations at evolutionarily conserved amino acids [12].

185 Interestingly, in animals carrying an *alg-1* NDD mutation heterozygous to a wild-type *alg-*
186 *1* allele, no lethality or abnormal *col-19::gfp* expression was observed (Figure S1A-B). Meanwhile,
187 the reduction of the number of progeny of the heterozygous mutants, if any, was not as
188 remarkable as for the corresponding homozygotes (Figure S1C). This indicates that the *alg-1*
189 NDD mutations, similar to the *alg-1* antimorphic mutations described previously, appear to be fully
190 recessive or only weakly semi-dominant [12]. Thus, the *alg-1* NDD mutations are not strictly
191 dominant negative in the classical sense, and their negative activities may be dosage dependent
192 or complemented by a WT allele.

193

194 **The C749-S750-H751 sub-region is critical for ALG-1 function.**

195 One of the previously-described *C. elegans alg-1* antimorphic mutations, *alg-1(ma192)*, is
196 a serine-to-phenylalanine point mutation at the amino acid homologous to S750 of *AGO1*, which
197 is adjacent to the H751L NDD mutation. In addition, another human genetic study of NDD patients
198 reported three independent cases of a cysteine-to-tyrosine change in *hAGO2* at the amino acid
199 homologous to C749 of *hAGO1* [21]. It is striking that three independent genetic screens in human
200 and *C. elegans* have recovered mutations at three adjacent Argonaute amino acids (C749Y,
201 S750F, and H751L) that seem to cause a particularly potent class of defects. The adjacency of
202 the three mutations suggests that these amino acids lie in a region of Argonaute protein critical
203 for function and may affect the activity of the protein similarly.

204 The current structure of co-crystallized *hAGO2::miRNA::target* ternary complex supports
205 the hypothesis that the C749-S750-H751 region could be particularly critical for Argonaute
206 function (Figure 2A) [30, 31]. The PIWI domain amino acids affected by the identified mutations
207 are positioned close to the backbone of the miRNA at g5-g6 seed nucleotides (Figure 2A).
208 Particularly, most atoms in the imidazole group of the H751 side chain are spatially close to the
209 atoms of the backbones of miRNA g5 and g6 nucleotides, with an average distance of 3.6 Å,
210 suggesting that the side-chain of H751 directly contacts the miRNA seed region via hydrogen
211 bonds and electrostatic force [32] (Figure 2A).

212 To further investigate and compare the functions affected by the C749, S750, and H751
213 mutations, we introduced the C749Y mutation into the *C. elegans alg-1* by CRISPR/Cas9, and
214 compared its phenotypes to those of *alg-1(S750F)* and *alg-1(H751L)* mutants. Like S750F and
215 H751L, *alg-1(ma545, C749Y)* mutant animals exhibited adult lethality, reduced number of
216 progeny, and abnormal *col-19::gfp* expression (Figure 2B). Moreover, all three mutants exhibited

217 a penetrance of the *col-19::gfp* expression defect that is greater than the *alg-1(null)* mutant,
218 suggesting that all these three mutations confer antimorphic activity to ALG-1 (Figure 2B). These
219 findings support the conclusion that the C749-S750-H751 sub-region is particularly critical for
220 certain Argonaute functions, such that mutations in this region can cause the mutant ALG-1
221 protein to antagonize the functions of ALG-2.

222

223 **The *alg-1* NDD mutations can disrupt total miRNA profiles and the profiles of miRNAs**
224 **associated with ALG-1.**

225 Previous studies of *C. elegans alg-1* antimorphic mutations reported global abnormalities
226 in miRNA biogenesis without affecting Argonaute protein levels [12, 29]. The expression levels of
227 the mutated ALG-1 NDD proteins similarly did not differ significantly from WT ALG-1, suggesting
228 that overall protein stability was not affected by these mutations (Figure 3). We then sought to
229 test whether the *alg-1* NDD mutations can cause similar perturbations in the expression of *C.*
230 *elegans* miRNAs. We performed small RNA sequencing (sRNA-seq) of total RNA from L4 larval
231 extracts and analyzed the expression levels of guide strands for the 259 relatively abundant
232 (minimal RPM > 5) miRNAs (Figure 3A-B, S2, S3, Table S1). We found that the F180 Δ and G199S
233 mutations caused a remarkable disturbance of total miRNA profiles, with 87 and 75 miRNAs,
234 respectively, perturbed more than 2-fold (FDR < 0.05) (Figure 3C-D). Only one miRNA was
235 changed in level with statistical significance in the V254I mutant (Figure S3), which is consistent
236 with the weak phenotypes of *alg-1(V254I)* (Figure 1D-H). Surprisingly, only 21 miRNAs were
237 significantly perturbed in the H751L mutants (Figure 3C-D), which is in sharp contrast with the
238 strong phenotypes of H751L mutant animals.

239 To determine whether the *alg-1* NDD mutations affect the profiles of miRNAs that
240 associate with the mutant ALG-1 protein, we performed ALG-1 immuno-precipitation (IP) using
241 anti-ALG-1 polyclonal antibody and sequenced the miRNAs co-immuno-precipitated with ALG-1
242 (Figure 3A-B, S2A). Consistent with the observed changes in total miRNAs (input), many miRNAs
243 showed altered association with mutant ALG-1 compared to the wild-type (Figure 3C-D, S2C-D,
244 S3, Table S1). Specifically, among the miRNAs that co-immuno-precipitated with ALG-1, 90
245 miRNAs for F180 Δ , 64 miRNAs for G199S, 14 miRNAs for H751L, and 0 miRNAs for V254I were
246 significantly changed compared to those co-immunoprecipitated with wild-type ALG-1 (Figure 3C-
247 D). The majority of the perturbed miRNAs that exhibited altered expression in the IP also had a
248 corresponding change in the input with statistically significant enrichment (Figure S2A).

249 It is noteworthy that while some miRNAs were perturbed in multiple NDD mutants, some
250 miRNAs were uniquely perturbed in individual mutants (Figure 3D). This observation underscores
251 the suggestion that different NDD mutations affect ALG-1 function differently, possibly reflecting
252 the unique functions of the affected protein domains (Figure 3D). In addition, large proportions of
253 the miRNAs disrupted in the NDD mutants were distinct from the miRNAs affected in the *alg-1*
254 *null* (Figure S2B), suggesting that the miRNA perturbations in the NDD mutants are not simply
255 caused by a reduction of *alg-1*'s normal contribution to miRNA biogenesis.

256

257 **The NDD mutations can alter guide/passenger strand ratios.**

258 In the previous report, *C. elegans alg-1* antimorphic mutations, including the *alg-1(S750F)*
259 mutation which is adjacent to H751L, disturbed miRNA biogenesis not only by changing miRNA
260 expression levels, but also by altering relative abundances of guide (miR) and passenger strands
261 (miR*) for particular miRNAs [12, 29] (Figure 4A). We therefore asked whether the *alg-1* NDD
262 mutations can similarly cause alterations in relative miR/miR* strand abundance. We found that,
263 for multiple miRNAs, the miR*/miR ratios were altered in the F180Δ, G199S and H751L mutants
264 (Figure 4B-D). In principle, an altered miR/miR* ratio can reflect altered guide-passenger selection
265 as discussed above, or defects that do not alter strand choice *per se*, but affect the relative stability
266 of the two strands, for example by a failure to dispose the passenger strand. To distinguish these
267 two scenarios, we examined the expression levels of guide and passenger strands of individual
268 miRNAs in the NDD mutants (Figure 4E). We observed that some of individual miRNAs exhibited
269 increased expression of miR* accompanied by decreased expression of the guide strands in the
270 NDD mutants, suggesting that the changed miR/miR* ratio could largely be attributed to a strand
271 selection defect (Figure 4E).

272

273 **The *alg-1* NDD mutations cause allele-specific translome-wide perturbations in gene** 274 **expression.**

275 The AGO protein is a core miRISC component and therefore is critical for post-
276 transcriptional gene regulation. Changes in ALG-1 functions could be expected to disrupt gene
277 expression profiles due to the de-repression of protein production from mRNAs directly targeted
278 by miRNAs, combined with indirect perturbation of genes downstream of disrupted miRNA targets.
279 To assess how the NDD mutations affect genome-wide gene expression as changes in translation

280 from each mRNA, we used ribosome profiling (Ribo-seq) to profile ribosome occupancy of
281 mRNAs in extracts of late L4 animals for the WT, *null*, and NDD mutants [33, 34]. We observed
282 that all the mutations can perturb the translome of the mutant animals compared to the WT
283 (Figure 5A, Table S2). The number of genes with statistically significant perturbations in ribosome
284 protected fragment (RPF) counts ($|FC| > 2$ and $p_{adj} < 0.1$) ranged from 66 genes (V254I) to 1731
285 genes (F180Δ) (Figure 5A). The gene expression changes were observed for both abundantly
286 expressed genes and genes with low expression levels (Figure S4F). PCA analysis suggests that
287 each NDD mutant exhibits a distinctively perturbed translome (Figure 5B), and the sets of genes
288 perturbed in the weaker mutants (i.e., V254I) were not simply a subset of the sets perturbed in
289 the stronger mutants (Figure 5C), suggesting that each mutation may impair ALG-1 function in a
290 qualitatively distinct fashion.

291

292 **The major heterochronic genes were translationally perturbed in NDD mutants.**

293 The *alg-1* NDD mutants exhibit adult lethality and *col-19::gfp* expression defects in the
294 hypodermis, consistent with disruptions in miRNA-regulated heterochronic pathway function. We
295 found that genes that were translationally up-regulated in *alg-1* NDD mutants are enriched for
296 genes expressed in hypodermal seam cells (Figure S4E). The enriched seam cell genes included
297 major heterochronic genes *daf-12*, *hbl-1*, and *lin-14* (Figure 5D). Gain-of-function mutations in
298 these genes have been reported to cause heterochronic phenotypes, and these genes have been
299 genetically confirmed to be miRNA targets [3, 26, 35-38]. We found that the translation of *daf-12*
300 and *hbl-1* was up-regulated in the F180Δ, G199S, and H751L mutants, and *lin-14* was up-
301 regulated in the F180Δ and H751L mutants (Figure 5D). This observation suggests that the
302 abnormal function of ALG-1 NDD miRISC causes over-expression of these heterochronic genes
303 and consequently leads to the developmental phenotypes in the *alg-1* NDD mutants. Meanwhile,
304 none of the major heterochronic genes were significantly perturbed in the V254I mutant,
305 consistent with the mild phenotypes of V254I animals.

306

307 **The NDD mutations cause antimorphic translome perturbations.**

308 Consistent with *alg-1* NDD mutations causing *alg-1* loss-of-function, the translationally
309 perturbed genes in *alg-1* NDD mutants partially overlap with the genes perturbed in the *alg-1 null*
310 mutants (Figure S4A). However, the translome perturbations of the NDD mutants are also
311 strikingly distinct from *alg-1 null* mutant because they include gene changes not observed in the

312 *alg-1(null)* (Figure 5E, set1, Figure S4B). In addition, some genes were found up-regulated in *alg-*
313 *1* NDD mutants but were down-regulated in the *alg-1 null* mutant (Figure 5E, set2, S4C). Other
314 genes were perturbed in both the *alg-1* NDD mutants and *alg-1 null* mutants but with greater
315 perturbation ($|\Delta\text{FC}| > 2$) in the *alg-1* NDD mutants than in the *null* mutant (Figure 5E, set3, S4D).
316 Together, these genes form a gene subset distinctly affected in *alg-1* NDD animals versus *alg-1*
317 *null* animals. We refer to these genes (set1-3) as antimorphic perturbed (*amp*) genes (Table S3).
318 For the F180 Δ , G199S, and H751L mutations, the occurrence of the *amp* gene perturbations in
319 excess of those in *alg-1 null* is consistent with the observation that these mutations cause
320 developmental phenotypes stronger than *alg-1 null* (Fig. 1D-H). Interestingly, even the weakest
321 mutation V254I, which displayed negligible visible phenotypes, nevertheless exhibited *amp* genes
322 of the set1 and set2 classes (Figure 5E). We propose that the perturbation of the *amp* genes may
323 contribute to the antimorphic phenotypes of *alg-1* NDD mutants and that all the NDD mutations
324 that we modeled in *C. elegans* confer an antimorphic impact on the ALG-1 protein in the context
325 of translome regulation.

326

327 **The translome disruptions in *alg-1* NDD mutants correspond to distinct profiles of** 328 **miRNA perturbation.**

329 The relatively mild perturbation of miRNA levels in the total miRNA and ALG-1 IP profiles
330 caused by the H751L mutation stands in striking contrast with the severity of the developmental
331 phenotypes, as well as the substantial perturbations in the translome exhibited by H751L
332 mutants. Specifically, the H751L mutation causes stronger developmental phenotypes and gene
333 perturbation than G199S (Figure 1D-F, Figure 5A-B). However, the number of miRNAs whose
334 total abundance or ALG-1 association is reduced in the H751L mutant are far less than the
335 number of miRNAs reduced in the G199S mutant (Figure 3C-D). This contrast suggests that the
336 stronger phenotypes of H751L mutant animals reflect a substantial loss of miRNA function that is
337 not reflected by miRNA levels. We therefore hypothesized that the H751L mutant ALG-1 protein,
338 although relatively normal for miRNA biogenesis/association, is defective in one or more
339 subsequent functions in miRISC maturation or function. Moreover, by binding an essential
340 repertoire of miRNA guides, the ALG-1(H751) protein, which is incapable of target repression,
341 sequesters a large set of miRNAs that would otherwise associate with ALG-2 to function in the
342 absence of ALG-1 (Figure 6A). We reason that such a sequestration effect can account for the
343 majority of the antimorphic effect of H751L, where the mutant exhibits a stronger phenotype than

344 the *null* mutant, without a major impact on miRNA levels. For other *alg-1* NDD mutations that
345 substantially affect the levels of more miRNAs, the overall phenotype could reflect a combination
346 of both altered miRNA levels and sequestration of miRNAs in defective miRISC.

347 Following the model above, we propose that each of the *alg-1* NDD mutations cause a
348 certain amount of net loss-of-function (*lof*) for specific miRNAs that is a combination of two effects:
349 the reduction in the overall level of that miRNA and the sequestration of that miRNA into non-
350 functional miRISC. To capture these two components in a single numerical estimate of *lof* for
351 individual miRNAs in each *alg-1* NDD mutant, we derived a net repressive functionality score
352 (NRF.score; see Materials and Methods), which represents the proportional target repressive
353 functionality of that particular miRNA in the mutant compared to the WT (NRF.score_{WT} = 1;
354 NRF.score_{null} = 0). The NRF.score captures the contribution from miRNA level reduction by
355 incorporating input miRNA fold change compared to the WT. Meanwhile, the NRF.score also
356 captures the contribution from sequestration of miRNAs in defective ALG-1 miRISC by
357 incorporating two values: 1) the enrichment of the miRNA co-immunoprecipitation with ALG-1 in
358 the mutant compared to the WT, and 2) the intrinsic function of the mutant ALG-1 protein
359 determined by the penetrance of the lethality of *alg-1* mutant in *alg-2(null)* genetic background
360 (Figure 1H).

361 We calculated the NRF.score of the 76 most abundant miRNAs (minimum RPM >15) and
362 found that the numbers of miRNAs with NRF.score below an arbitrary threshold for *lof* (NRF.score
363 < 0.5) were 44 for H751L, 45 for F180Δ, 22 for G199S, and 1 for V254I (Figure 6B, Table S4).
364 Notably, by modeling overall miRNA functionality as sequestration in combination with perturbed
365 levels, the NRF.score identified a larger number of miRNAs functionally affected by the H751L
366 mutation, potentially reconciling the disconnection between the strong *alg-1(H751L)* phenotype
367 compared to the mild effects of miRNA abundances.

368 To test whether modeling miRNA function according to NRF.score is consistent with the
369 observed translome disruption, we identified sets of putative disrupted miRNA targets for each
370 mutant (145 for H751L, 396 for F180Δ, 81 for G199S, and none for V254I) that were translationally
371 up-regulated and that also contain predicted target sites for the miRNAs with a *lof* NRF.score in
372 that mutant. For the H751L, F180Δ, and G199S mutants, the corresponding putative disrupted
373 miRNA targets were statistically enriched among all translationally up-regulated genes, compared
374 to the target genes of just down-regulated miRNAs (Figure S5). These results support the model
375 that the expression of mutant ALG-1 NDD protein in *C. elegans* can cause miRNA loss-of-function

376 by the combined effects of disrupted miRNA biogenesis and sequestration of miRNAs in defective
377 ALG-1 miRISC.

378

379 **The *alg-1* NDD mutations have distinct impacts on translational repression and mRNA**
380 **abundance.**

381 miRNA-mediated post-transcriptional gene regulation can occur via translational
382 repression and/or mRNA destabilization, such that impaired miRNA activity can manifest as
383 increased translational efficiency (TE) and/or increased abundance of target mRNAs, respectively
384 [33, 39]. To assess how the *alg-1* NDD mutations affect these two modes of target repression, we
385 analyzed our ribosome profiling results in conjunction with RNA-seq analysis of total mRNA (Table
386 S2). For the RNA-seq, we employed ribosomal RNA depletion for mRNA enrichment to ensure
387 the quantitative recovery of all mRNAs regardless of poly(A) status [40]. The translational
388 efficiency (TE) of each transcript was calculated by normalizing the RPF values with mRNA
389 abundance [38]. We evaluated the TE and mRNA abundance of genes that were up-regulated in
390 the translome and that also contain predicted target sites for miRNAs with a *lof* NRF.score in
391 each mutant. These genes were categorized into three de-repression modes: (a) genes that
392 exhibit statistically significant up-regulation in TE but no significant change in mRNA abundance,
393 referred to as “TE up”; (b) genes that exhibit statistically significant up-regulation in mRNA
394 abundance but no significant change in TE, referred to as “mRNA up”; (c) genes that exhibit
395 statistically significant up-regulation in both TE and mRNA abundance, referred to as “both
396 up”(Figure 7B). We found that in the F180Δ, G199S, and H751L mutants, 79.2%, 79.1%, and
397 34.5% of the translationally up-regulated targets of *lof* miRNAs exhibit a statistically significant
398 increase in TE and/or mRNA abundance (“TE up”, “mRNA up” or “both up”) (Figure 7C).
399 Interestingly, 61.0% of these genes in the H751L mutant were de-repressed with increased
400 translational efficiency without a significant change of mRNA abundance (“TE up”), whilst only
401 13.7% and 6.2% for the F180Δ and G199S mutants were de-repressed via “TE up” mode (Figure
402 7C).

403 The contrast in TE disruption bias associated with H751L could indicate that different ALG-
404 1 NDD mutations can have selective disruptions of intrinsic functionalities of the ALG-1 protein,
405 leading to distinct effects on the downstream target repression mechanism. However, an
406 alternative explanation could be that the H751L mutation happens to preferentially disable the
407 activity of a subset of miRNAs that are enriched for those with TE-regulated targets. To distinguish

408 between these possibilities, we selected the set of miRNAs with a *lof* NRF.score in all F180 Δ ,
409 G199S, and H751L mutants and analyzed the targets repression of these commonly affected
410 miRNAs (Figure 7D). We found that the targets of the commonly affected miRNAs also showed
411 a similar TE-only enrichment in the H751L mutant compared to F180 Δ and G199S (Figure 7E-F).

412 Additionally, we found that the TE de-repression bias of H751L applies even to specific
413 target genes. We analyzed the subset of 46 genes with “TE up” de-repression mode in the H751L
414 mutant and compared the de-repression modes of these identical genes in the F180 Δ or G199S
415 mutants. We found 44 of the 46 genes were also de-repressed in F180 Δ , and 25 out of those 44
416 genes exhibited a shift of the mode of de-repression from H751L to F180 Δ . Similarly, 8 of the 46
417 genes de-repressed in H751L were also up-regulated in G199S, and all 8 genes exhibited a mode
418 shift from H751L to G199S (Figure 7G). This suggests that the distinction in the target de-
419 repression mode associated with individual NDD mutations is directly related to ALG-1 protein
420 function, and not an indirect effect of selective disruption of unique sets of miRNAs or targets. We
421 thus conclude that the H751L mutation may directly impair the target repression functionality of
422 ALG-1 in a way distinct from the F180 Δ and G199S mutations, perhaps reflecting discrete
423 functions of the mutated amino acids and/or different roles in target repression mode for the PIWI
424 and L1 domains where these mutations localize.

425

426 **The *alg-1* NDD mutations can perturb the expression of genes with human orthologs**
427 **expressed in brain translomes and/or related to NDD.**

428 The documentation of the hAGO1 mutations in human NDD patients raises the question
429 of whether the perturbed genes in *C. elegans* NDD mutants include genes whose human
430 homologs could be related to the pathogenesis of NDD. We examined the homology between the
431 perturbed genes in *C. elegans alg-1* NDD mutants and the genes translationally expressed in
432 human central nervous system [41, 42]. We found that among the *C. elegans* genes that were
433 translationally perturbed in the *alg-1* NDD mutants, 262 genes for F180 Δ , 61 genes for G199S, 6
434 genes for V254I, and 79 genes for H751L have human orthologs which are expressed in human
435 brains translomes (Figure 8A-B) [41, 42]. 55% for F180 Δ , 34% for G199S, 0% for V254I, and
436 58% for H751L of these genes have target sites for the miRNAs with *lof* NRF.score (Figure S7).
437 Of the neuronally-expressed human/worm homologous genes disrupted in *C. elegans alg-1* NDD
438 mutants, 52 genes for F180 Δ , 13 genes for G199S, 3 genes for V254I, and 16 genes for H751L
439 have been reported to be genetically associated with human NDDs with ID symptoms and

440 definitive sysNDD entry [41, 43] (Figure 8C, Table S5). This observation suggests that the
441 perturbation of these genes may contribute to the clinical manifestations observed in NDD
442 patients from whom the mutations were identified.

443

444 **The translome perturbation in the *alg-1* NDD mutants may trigger stress-related**
445 **responses due to proteome imbalance.**

446 Protein homeostasis (proteostasis) is tightly controlled and critical for normal cellular
447 physiology. An imbalance in the proteome induced by genetic or other perturbations can impair
448 proteostasis and contribute to pathogenesis [44, 45]. In normal cells, proteome imbalance elicits
449 the activation of stress response pathways to restore proteostasis [46, 47]. For example, a recent
450 study shows that aging-induced proteome imbalance in *C. elegans* can trigger stress responses
451 due to abnormal protein aggregation [48]. In the *alg-1* NDD mutants, a large proportion of protein-
452 coding genes have been translationally perturbed, especially in the F180 Δ and H751L mutants
453 (9.0% of total protein-coding genes for F180 Δ and 3.4% for H751L). Accordingly, we found that
454 stress-related genes are significantly enriched in the translationally up-regulated genes in all four
455 NDD mutants, suggesting that the perturbation of translomes may be leading to proteome
456 imbalance, which consequently triggers stress responses (Figure 9A, S7A) [49, 50]. The F180 Δ ,
457 G199S, and V254I mutants also exhibited up-regulation of small heat shock protein (HSP) genes,
458 which encode chaperons that buffer insoluble protein aggregation [51] (Figure S7B), and the
459 unfolded protein response (UPR)-related genes are also statistically enriched in the translationally
460 up-regulated genes for all of the NDD mutants (Figure 9B), indicating that stress responses may
461 be triggered by the misfolding and aggregation of proteins expressed at abnormally high levels in
462 the mutants. Meanwhile, no significant changes were seen for the expression levels of large heat
463 shock proteins orthologous to HSP70/HSP90, and no global up-regulation of proteasome
464 components and proteolysis-related genes [52, 53] was observed (Figure S7C-D).

465 It is also noteworthy that the perturbation of small HSP genes was only observed for the
466 F180 Δ , G199S, and V254I mutants, but curiously, not in the H751L or *null* mutants (Figure S7B).
467 The observation that the *alg-1* H751L and *null* mutant do not display the up-regulation of small
468 HSP may suggest that proteome stress can be allelic specific and is not necessarily an inevitable
469 consequence of disrupting miRISC function, but rather related to the particular repertoire of
470 proteins dysregulated in the particular mutant.

471

472 **Discussion**

473 **Modeling *hAGO1 de novo* coding variants in *C. elegans* enables the**
474 **characterization of novel allele-specific Argonaute functions.**

475 Argonaute proteins of the Ago class contribute to miRNA biogenesis, as well as mRNA
476 target recognition and repression [54]. Accordingly, depletion of AGO genes by RNAi or mutation
477 can impair miRNA biogenesis and trigger miRNA target de-repression [6, 7, 23]. Structural studies
478 of mammalian Argonautes and analyses of the evolutionary conservation of Argonaute amino
479 acid sequences provide insights into the functional architecture of Argonautes and the functional
480 importance of specific amino acids [6, 30, 32, 54, 55]. For example, D597, D669, and H807 are
481 confirmed as key residues for the catalytic activity of slicing by hAGO2, and amino acids M47,
482 D95, and F181 are known to critically contribute to the unwinding of miRNA duplex during the
483 process of loading [56, 57]. Other functionally key residues have been revealed by forward genetic
484 screens, exemplified by G553 and S895, for which mutations at the corresponding amino acids
485 in *C. elegans* ALG-1 can impair miRNA biogenesis and guide-passenger strand selection [12, 29].

486 The recently described *de novo* mutations in *hAGO1* and *hAGO2* carried by NDD patients
487 point to the significance of the corresponding amino acids in AGO function [20, 21]. It is
488 noteworthy that most of the amino acids mutated in these patients, although phylogenetically
489 conserved, had not been explicitly linked to AGO functions by previous studies. Thus, genetically
490 modeling specific AGO mutations identified in human patients in an experimental animal promises
491 to help elucidate novel functions of AGO proteins.

492 In this study, we chose four *hAGO1* mutations to model in *C. elegans* ALG-1 based on
493 either of two criteria: (1) they were documented in multiple independent families (F180 Δ , G199S,
494 V254I) or (2) the mutation is adjacent to a previously identified phenocritical residue (H751L). We
495 find that the *alg-1* NDD mutant proteins are expressed in *C. elegans*, associate with miRNAs, and
496 cause visible phenotypes stronger than *alg-1 null*. Further, we find that the *alg-1* NDD mutations
497 disrupt miRNA profiles in *C. elegans*, and cause patterns of transcriptome perturbation distinct from
498 *alg-1 null* mutant. These properties are consistent with the antimorphic mutation model applied to
499 a previously-described class of *C. elegans alg-1* mutations [12].

500 Notably, the severity of the *C. elegans* developmental phenotypes of the *alg-1* NDD
501 mutants is consistent with symptom severity in the NDD patients. In *C. elegans*, F180 Δ and H751L
502 strongly impaired the viability, vulval integrity, and larval-to-adult differentiation of hypodermal
503 cells, while the G199S mutation conferred more moderate phenotypes and the V254I exhibited

504 nearly undetectable phenotypes. Similarly, the H751L patients (monozygotic twins, $n = 1$) exhibit
505 severe ID with growth delay, microcephaly, speech impairment, motor delay, feeding difficulty,
506 facial dysmorphia, and F180 Δ patients ($n = 9$) exhibit mild-to-severe ID and motor delay, and
507 some patients developed epilepsy, facial dysmorphia, growth retardation [20]. In contrast, the
508 G199S patients ($n = 9$) exhibit mild-to-moderate ID with speech impairment, epilepsy, motor delay,
509 and facial dysmorphia for some patients. Meanwhile, the V254I patients ($n = 2$) exhibit the least
510 severe symptoms with mild ID, speech delay, epilepsy, and hyperactivity but no motor delay or
511 additional features (no growth retardation or MRI anomalies) [20]. This broad correspondence of
512 phenotypic severity between the two systems suggests that the mutations may impair the
513 Argonaute protein in a similar fashion, highlighting the utility of model organisms to study human
514 genetic disorders.

515 Interestingly, the four NDD mutations displayed distinctive impairment of AGO functions
516 in *C. elegans*. Additional to the distinctive developmental phenotypes discussed above, these
517 mutations also differed in their effects on miRNA biogenesis and gene expression in several ways:
518 (1) The severity of perturbations in miRNA levels and translomes varied between different
519 mutants; (2) The profiles of disturbed miRNAs and gene expression were distinct for each mutant;
520 (3) The mutations displayed allele-specificity in their relative impacts on target mRNA abundance
521 versus translational efficiency. Furthermore, the severity of phenotypes, miRNA perturbations,
522 and translome perturbations was not strictly correlated among the four *alg-1* NDD mutations.
523 The distinctions in developmental and molecular phenotypes between different NDD mutations in
524 *C. elegans* suggest the mutated amino acids have differing mechanistic impacts on *in vivo*
525 functions of ALG-1 protein.

526 Currently, we do not have direct structural or biochemical evidence to illuminate
527 specifically how the different NDD mutations modeled here could impair AGO protein functions.
528 However, our results suggest possible mechanisms in light of current structural models. According
529 to the current understanding of hAGO2 crystal structure, H751 resides inside the PIWI-MID
530 channel where the miRNA seed region duplexes with the target RNA. The imidazole group in the
531 H751 side chain is close to the backbone of g5 and g6 nucleotides of the miRNA and likely
532 contacts the backbone phosphates via hydrogen bonds and electrostatic forces [32]. In H751L
533 mutant ALG-1, the change from histidine to leucine alters the charge and hydrophobicity of the
534 side chain and thereby may impair the interaction between the residue and the miRNA.
535 Interestingly, we found that mutations at the two residues preceding H751 (S750F, and C749Y)
536 can also strongly impair ALG-1 function, as revealed by the strong developmental phenotypes of

537 the mutants. Since each of the S750F and C749Y mutations alters the hydrophobicity and spatial
538 size of the side chains, these mutations may change the positioning of H751 and consequently
539 prohibit it from interacting properly with the miRNA. The changes in the side chain size and
540 hydrophobicity in these mutations may also result in allosteric distortion of ALG-1 protein and
541 impair function associated with more distant domains of ALG-1.

542 A recent study of *Arabidopsis thaliana* Argonaute AtAGO10 suggests that a β -hairpin of
543 L1 domain, which is conserved in eukaryotic AGOs, contacts the t9-t13 of target RNA by
544 electrostatic forces and consequently coordinates the pairing between 3' non-seed region of
545 miRNA and target [58]. Interestingly, the L1 β -hairpin includes the residue homologous to *hAGO1*
546 F180 and is sterically adjacent to the residue homologous to *hAGO1* G199 (Figure S8). Moreover,
547 the structure of the human AGO2::miRNA::target complex suggests that the β -hairpin resides
548 sterically adjacent to t11-t13 of the target RNA (Figure S8B) [31]. Recent genetic and biochemical
549 studies have shown that such 3' pairing, especially at t11-t13, can be critical to the proper
550 regulation of certain miRNA/targets [38, 59]. Thus, although F180 and G199 residues do not
551 directly contact the 3' duplex of miRNA/target, the F180 Δ and G199S mutation may disrupt 3'
552 pairing by distorting the sub-regional conformation of the L1 β -hairpin or hinder its movement,
553 and consequently impair target repression, especially for the miRNA/target interactions that
554 requires 3' pairing. Moreover, extrapolating from the AtAGO10 structure in the slicing
555 configuration, where the L1 β -hairpin interacts with the non-guide strand of the helical
556 miRNA::target duplex, it is possible that the F180 Δ and G199S mutations could disrupt
557 interactions of the L1 β -hairpin with the passenger strand of AGO::pre-miRNA complexes. Such
558 a hypothetical interaction is consistent with our results that the F180 Δ and G199S mutations
559 disrupt of miRNA biogenesis.

560 In contrast, the V254 residue is neither directly interacting with the miRNA::target duplex
561 nor involved in sub-regions with specific functions that have been structurally or biochemically
562 characterized. According to the current structure, the V254 side chain is exposed on the surface
563 of the AGO protein, enabling it to potentially contact other protein factors. Thus, the V254I
564 mutation may impair AGO protein function by impacting inter-molecular interactions with other
565 proteins.

566

567 **Molecular mechanisms of the *antimorphic* effect of *alg-1* NDD mutations.**

568 It is striking that the reported *hAGO1* and *hAGO2* NDD mutations are mostly single amino
569 acid changes [20-22]. The rarity of frameshift, truncation, or large deletions suggests that single-
570 gene *hAGO null* mutations are either not tolerated or do not cause observable symptoms. For
571 *hAGO2*, the rarity of *de novo null* mutations in NDD patients could be due to the critical
572 contribution of *hAGO2* to miR-451 biogenesis, which is essential for erythropoiesis and erythroid
573 homeostasis in mammals [23, 60, 61]. Interestingly, *null* mutations of *hAGO1* in NDD patients
574 have been reported as large deletions that also delete the nearby *hAGO3* and *hAGO4* genes [18,
575 19]. This suggests that *hAGO1*, *hAGO3*, and *hAGO4* are redundant, and that diagnosable
576 phenotypes do not arise unless the activity of multiple AGO genes is defective. If this is so, how
577 could the reported point mutations in *hAGO1* or *hAGO2* result in phenotypes? This question
578 motivates the antimorphic model for the action of the *hAGO1* NDD mutations, wherein the mutant
579 AGO protein impairs miRNA activity by competing with otherwise redundant paralogous AGO
580 proteins. In this model, the mutant AGO protein is expressed and can associate with miRNAs but
581 is functionally defective in target repression. Consequently, a large fraction of miRNAs in the cell
582 is sequestered in non-functional complexes, depleting the supply of miRNAs available to
583 paralogous AGO proteins.

584 In this study, we show that the H751L and F180 Δ mutations are antimorphic for *alg-1* in
585 *C. elegans* because the mutants exhibit heterochronic phenotypes with greater penetrance than
586 that of the *alg-1 null* mutant. The antimorphic effect of H751L and F180 Δ is similar to the results
587 from Zinovyeva et al. 2014 where the *alg-1(ma192)* (corresponding to S750F for *hAGO1*) and
588 *alg-1(ma202)* (corresponding to G571R for *hAGO1*) mutations exhibit a similar antimorphic effect
589 on *C. elegans alg-1* [12]. These parallels suggest that these human and *C. elegans* AGO
590 mutations may similarly result in the expression of mutant Argonaute proteins that can associate
591 with miRNAs but that are functionally defective in target repression, and hence sequester miRNAs
592 in non-functional miRISC.

593 The sequestration model is consistent with our results. In particular, we found that the
594 H751L mutation only mildly disturbed the profiles of total miRNA expression or the profiles of
595 miRNA co-immunoprecipitated with mutant ALG-1. The mild disturbance of miRNA profiles
596 suggests that ALG-1^{H751L} supports essentially normal miRNA biogenesis and miRISC assembly,
597 but that the ALG-1 miRISC may be defective in target recognition and repression. Considering
598 the possibility that the H751L mutation could impair the interaction of ALG-1 with the backbone of
599 the miRNA seed region (Fig. 2A), it is possible that the H751L mutation prevents the functional

600 interaction of miRISC with targets. Thus, in the case of H751L, the antimorphic effect could result
601 largely from the sequestration of miRNAs in miRISC complexes that are unable to bind targets.
602 We also note that, in principle, antimorphic mutations could disrupt miRISC function at step(s)
603 after target binding. In this scenario, non-functional miRISC would bind the targets and
604 competitively inhibit access to the target by miRISC containing other AGO proteins, essentially
605 exerting a blocking effect in addition to the sequestration effect.

606 Furthermore, *alg-1* antimorphic mutants can exhibit potent disruption of guide/passenger
607 strand selection [29], which could in principle result in essentially neomorphic miRNA phenotypes
608 in cases where the normally degraded passenger strand accumulates to functional levels. If the
609 mutant ALG-1 miRISC were to retain partial function -- as is the case for the G199S and V254I
610 mutants which are viable in *alg-2 null* background -- then ALG-1 miRISC containing hyper-
611 abundant passenger strands could repress target genes which are not supposed to be regulated
612 by miRNAs. Such neomorphic effects can also contribute to the production of phenotypes distinct
613 from the *null* mutant.

614

615 **The pleiotropy of AGO functions and the pathology of the AGO NDD mutations.**

616 In this study, we show that the *alg-1* NDD mutations can globally perturb translome in
617 *C. elegans*. Although the severity of translome perturbation varied among different mutations,
618 the stronger mutations were observed to disrupt remarkable proportions of the translome.
619 Meanwhile, some NDD mutants also exhibit strong developmental defects, including F180 Δ and
620 H751L, which are embryonically arrested in *alg-2 null* genetic background. These global
621 perturbations in gene expression and severe developmental defects are consistent with the
622 extensive pleiotropy of AGO-mediated miRNA regulation.

623 The perturbation of gene expression caused by *alg-1* NDD mutations was not only
624 extensive but also remarkably distinct, with each mutant exhibiting sets of disrupted genes that
625 were unaffected in the other mutants. Extending these observations to hypothetical effects of the
626 corresponding mutations in *hAGO1*, it is reasonable to suggest that similar extensive and partially
627 allele-specific gene expression disruptions could occur in the patients with *hAGO1* or *hAGO2*
628 NDD mutations. Here, a key question arises: could NDD pathology result from the dis-regulation
629 of a small set of specific genes whose over-expression is causative for NDD and that happen to
630 be dis-regulated in common by all the mutations? We suggest that this scenario is possible and
631 warrants further investigation in mammalian systems. However, the distinctions among the *C.*

632 *C. elegans alg-1* NDD mutations, both in distinct repertoires of disrupted miRNAs and distinct profiles
633 of downstream gene perturbations, suggest that NDD pathology in human patients could reflect,
634 at least in part, the emergent physiological and developmental consequences of broad dis-
635 regulation of gene expression networks. This supposition is consistent with the observation that
636 even among patients carrying identical *hAGO1* or *hAGO2* NDD mutations, there is still variability
637 of clinical manifestation compared to some other NDD syndromes [20, 21, 62].

638 The AGO NDD mutations can be thought of as triggering cascades of gene expression
639 dis-regulation (Figure 9C). We found that the *alg-1* NDD mutations can disrupt the processing,
640 loading, and/or function of multiple miRNAs. Since individual miRNAs can have dozens to
641 hundreds of targets, it is expected that the immediate impact of *alg-1* NDD mutations would
642 include de-repression (or neomorphic repression in the case of altered miRNA strand selection)
643 of a large set of direct targets. Perturbations of direct miRNA targets, particularly regulatory gene
644 products such as RNA binding proteins and transcription factors, should in turn lead to amplified
645 downstream disruptions of gene regulatory networks. The disrupted gene sets, including direct
646 miRNA targets and the indirectly affected downstream genes, can include sets of genes
647 expressed in the nervous system and/or with human homologs genetically linked to NDD-related
648 phenomena (Figure 8).

649 Among the potential physiological impacts of global dis-regulation of gene expression in
650 NDD mutants, it seems appropriate to consider the cellular and organismal stress of proteome
651 imbalance. We observed a statistically enriched up-regulation of the expression of stress-related
652 genes in some of the *C. elegans alg-1* NDD mutants. This up-regulation includes small heat shock
653 proteins, which is indicative of a proteome imbalance-induced protein aggregation [48, 52, 63].
654 Thus, one physiological trigger underlying the pathological effects of the AGO NDD mutations
655 could originate from cellular and organismal responses to the disturbance of proteostasis caused
656 by global perturbation of gene expression (Figure 9C).

657

658 **ACKNOWLEDGMENT**

659 We thank the members of Ambros Lab, Mello Lab, and Zinovyeva lab for the project
660 discussion. We thank Brittany Morgan and Francesca Massi for commenting on the structural
661 modeling. This research was supported by funding from NIH grants R01GM088365,
662 R01GM034028, R35GM131741 (VA), and R35GM124828 (AZ). Some *C. elegans* strains were

663 provided by the CGC, which is funded by the NIH Office of Research Infrastructure Programs
664 (P40 OD010440).

Author Contributions

665 Conceptualization: YD, AP, AZ, VA; Methodology: YD, LL, GPP, AZ, VA; Formal analysis: YD,
666 LL, GPP; Investigation: YD, LL, GPP; Resources: AZ, VA; Data curation: AZ, VA; Writing -original
667 draft: YD, AZ; Writing -review & editing: YD, LL, AZ, AP, VA; Supervision: AZ, VA; Project
668 administration: VA; Funding acquisition: AZ, VA.

Declaration of Interests

669 The authors declare no competing interests.

670

671 METHODS

672 *C. elegans* culturing and synchronization

673 *C. elegans* were cultured on nematode growth medium (NGM) and fed with *E. coli* HB101. To obtain
674 populations of synchronized developing worms, gravid adults were collected and washed twice with water.
675 Pellets of centrifuged worms were treated with 5 ml 1N NaOH and 1% (v/v) sodium hypochlorite for 4 min
676 with shaking to obtain embryos, and the embryos were rinsed with M9 buffer three times. The embryos
677 were hatched in 10 ml M9 buffer at 20°C for 16-18 hrs with mild shaking. Hatched L1 larvae were transferred
678 to plates at 30-50 worms per plate and replicate plates were cultured at 15°C, 20°C, or 25 °C for defined
679 periods of time; samples of the population were examined by microscopy to confirm the developmental
680 stages at the time of harvest.

681

682 CRISPR/Cas9 targeted mutagenesis at the *alg-1* genomic locus

683 Templates for ssDNA HR donors with 45-60 nt flanking the mutated nucleotide(s) were obtained from IDT.
684 To generate the V254 and H751L mutants, CRISPR/Cas9 RNP mixtures were injected into N2 animals at
685 the following final concentrations: Alt-R Cas9 (1.9 µM, IDT, cat# 1081058), AltR_Cas-9_crRNA_dpy-
686 10_cn64 (0.4 µM, IDT) [64], two AltR_Cas-9_crRNA_alg-1_H751/V254 crRNAs specific for the edited
687 regions (0.6 µM each, IDT), Alt-R tracrRNA (1.6 µM, IDT, cat# 1072532), and *alg-1* H751L or V254I donor
688 (160 ng/µL) in Cas9 RNP annealing buffer (1x, IDT, cat# 11010301). The Cas9 RNP mixtures were

689 incubated at 37°C for 5 minutes, and spun down for 2 minutes at 14000 RCF prior to injections. To generate
690 the F180Δ/G199S/C749Y mutants, CRISPR/Cas9 RNP mixtures were injected EG9615 animals which
691 express transgenic Cas9 from *oxIs1091* integrated transgene [65] at the following final concentrations:
692 AltR_Cas-9_crRNA_dpy-10_cn64 (0.86 μM, IDT), AltR_Cas-9_crRNA_alg-1_F180/G199/C749 crRNA
693 specific for the edited regions (2.6 μM, IDT), Alt-R tracrRNA (3.5 μM, IDT, cat# 1072532), and 120 ng/μl
694 ssDNA donor in 1X duplex buffer (Table S6).

695 F1 dumpy and/or non-dumpy animals were isolated from dumpy jackpot plates and genotyped by PCR and
696 restriction digestion using HpyCH4IV (F180Δ, NEB R0619), HinfI (G199S, NEB R155S), AflIII (V254I, NEB
697 R0541S), RsaI (C749Y, NEB N0167S) and DdeI (H751L, NEB R0175), followed by Sanger sequencing.
698 Mutants were backcrossed with N2 at least twice to remove *dpy-10*, *oxIs1091*, or other potential background
699 mutations.

700

701 **Phenotypic assays for vulva defects**

702 The adult lethality which results from the rupture of the young adult animal at the vulva (burst) or matricide
703 by offspring hatching in the uterus (bag) was scored after approximately 36 hrs (15°C), 24 hrs (20°C) or 16
704 hrs (25°C) of development (when at least 95% of the population had reached the adult stage). To score
705 viable progeny per adult, young adults were transferred to a fresh plate every 12 hrs until those capable of
706 laying eggs had completed egg-laying. Only hatched eggs were counted.

707

708 **Microscopy and heterochronic phenotypes**

709 Differential interference contrast (DIC) and fluorescent microscopy were performed on Zeiss.Z1 or Leica
710 DM6 B compound microscopes equipped with epifluorescence capabilities. *col-19::gfp* patterns were
711 scored by 10X or 63X objective. Fluorescent images were obtained on Zeiss.Z1 equipped with ZEISS
712 Axiocam 503 camera and processed by ImageJ FIJI [66].

713

714 **Total RNA preparation**

715 Harvested worms were washed with M9 medium, centrifuged, and the worm pellets were flash-frozen in
716 liquid nitrogen. The worm pellets were thawed and lysed by adding 4X volumes of QIAzol (Qiagen, Cat:
717 79306) and shaking vigorously at room temperature for 15 min. The total RNA was extracted by the addition
718 of 0.85X volume chloroform, centrifugation, and recovery of the aqueous phase, which was then re-
719 extracted with 1 volume phenol:chloroform:isoamyl alcohol (25:24:1, pH = 6.3). Total RNA was then
720 precipitated by adding 1 volume of isopropanol and 1 μl GlycoBlue (Invitrogen, Cat: AM9516), followed by
721 incubation at -80°C for at least 30 min, and recovery by centrifugation at 25,000 rcf for 10 min at 4°C. The

722 supernatants were discarded, and the RNA pellets were subsequently washed twice with 70% (v/v) ethanol,
723 air-dried at room temperature for 5 min, dissolved in RNase-free water, and stored at -80°C.

724

725 **ALG-1 immunoprecipitation**

726 The synchronized fourth larval stage (L4) animals were collected and the worm pellets were flash-frozen in
727 liquid nitrogen and stored at -80°C until total protein lysate preparations. Protein lysates were obtained as
728 previously described [67]. ALG-1 immunoprecipitation and Western blotting were performed as previously
729 described [68].

730

731 **Small RNA sequencing**

732 Total ("input") lysates and "IP" samples were subjected to RNA preparation as described above. Purified
733 RNA was subjected to gel-based size selection as previously described [69]. NEXTflex Small RNA Library
734 Prep kit v3 (PerkinElmer, cat# NOVA-5132) was used to prepare libraries according to the manufacturer's
735 instructions, followed by size selection of final PCR products as previously described [69]. Libraries were
736 sequenced using the Illumina Nextseq500 platform at the Kansas State University Integrated Genomics
737 Facility.

738 Small RNAseq reads were checked for quality before and after filtering using FastQC v0.11.8
739 (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc>). Cutadapt tool was used to clip the adapter
740 sequence from 3' end (-a ATCTCGTATGCCGTCTTCTGCTTG -e 0.1). Reads were split into libraries using
741 fastx barcode splitter utility (http://hannonlab.cshl.edu/fastx_toolkit/index.html) and the remaining 3' end
742 and 5' adapter sequences were clipped. The randomers were trimmed and the reads with a final length
743 range of 17-29 nt were selected for further analysis. Reads were mapped to *C. elegans* genome (WS279)
744 using bowtie v1.2.2 [70, 71] allowing three mismatches in the alignment. Mature miRNA expression was
745 quantified using the miRDeep2 pipeline [72]. The DESeq2 package in R was used to perform differential
746 expression analysis [73].

747

748 **miRNA site prediction**

749 miRNA targets were predicted against the transcriptomic 3' UTR sequences using TargetScanWorm
750 version 6.1 [74]. Sites with full complementarity to g2-g7 of the miRNA seed were retained. Sites with a
751 seed mismatch at g5-g8 accompanied by a full pairing of g13 through g16 were also retained. Differential
752 expression analysis was performed by DESeq2, significance indicates FDR (<0.05).

753

754 Ribosome profiling

755 Synchronized populations of developing worms were cultured at 20 °C for 45 hrs after feeding. Worms
756 harvest, monosome preparation, ribosome protected footprint (RPF) cloning and data analysis were
757 performed as previously described [38] except that the RPF libraries were prepared using NEBNext
758 Multiplex Small RNA Library Prep Set for Illumina (NEB E7300). The trimmed RPF reads were mapped to
759 *C. elegans* genome WS279 [75]. Genes with $|FC| > 2$ and $p.adj < 0.1$ (*DESeq2*) were considered
760 translationally perturbed genes with statistical significance.

761

762 RNA-seq and translational efficiency (TE)

763 Worm samples for RNA-seq were aliquoted from the ribosome profiling harvests before the lysis step and
764 frozen separately. The mRNA was enriched by ribosomal RNA (rRNA) depletion as described in [40], with
765 additional ASO oligos to deplete small recognition signal RNA (srpR). Library preparation and RNAseq data
766 analysis were performed as described in [38]. To calculate the TE, a pseudo count of 0.1 were added to
767 each gene for all samples. Genes with $|FC| > 1.5$ and $p.adj < 0.1$ (*DESeq2* for RNA abundance and Student's
768 t-test for TE) were considered as significantly perturbed genes. The ASO sequences can be provided upon
769 request.

770

771 Calculation of Net repressive functionality score (NRF.score)

772 The relative functionality of a given miRNA (miR_{*i*}) in a particular *alg-1* mutant (mut.) is calculated as:

$$773 \text{NRF.score}_i = \text{FC_input}_i \cdot [1 - (1-r) \cdot k_{mut.}] \text{ ---- (1)}$$

774 In equation (1), **FC_input_{*i*}** indicates the fold change of total miR-*i* in the mutant, which is expressed as

$$775 \text{FC_input}_i = \frac{\text{RPM.input.mut.}}{\text{RPM.input.wt.}}$$

776 r ($0 \leq r \leq 1$) is the relative intrinsic functionality of mutant ALG-1 and is calculated by $r = (1 - \frac{\%lethality.mut.}{\%lethality.null})$

777 in the *alg-2* null genetic background (i.e., since the lethal phenotype of *alg-1(V254I);alg-2(0)* has a
778 penetrance of 9.98%, r_{V254I} is 0.9002). Thus **(1-r)** represents the proportion of inactivated repressing
779 functionality of ALG-1.

780 k ($0 \leq k \leq 1$) is the enrichment of the miR-*i* that is co-immunoprecipitated with mutant *ALG-1*, which is
781 expressed as $k = \frac{\text{RPM.IP}}{\text{RPM.input} + \text{RPM.IP}}$. Thus, equation (1) can also be expressed as:

$$782 \text{NRF.score}_i = \text{FC_input}_i \cdot [1 - [(1-r) \cdot (\frac{\text{RPM.IP}}{\text{RPM.input} + \text{RPM.IP}})_{mut.}]]$$

783 For the *alg-1* null mutant, $r=0$, therefore,

784 **$NRF.score_{null} = FC_input_{null}$**

785

786 **Quantification and statistical analysis**

787 p-values representation is as follow: 0.05-0.01(*); 0.01-0.001(**); 0.001-0.0001(***); <0.0001(****). The

788 brood size/numbers of progeny phenotypes were analyzed by Student's t-test (two-tailed, unpaired). The

789 lethality and *col-19::gfp* expression phenotypes were analyzed by Fisher's test. Error bars indicate mean \pm

790 SD. Significance tests were conducted with Prism 9.

791

792 **FIGURE LEGENDS**

793 **Figure 1. The NDD mutations cause loss-of-function and antimorphic phenotypes in the *C.***
794 ***elegans* Argonaute *alg-1*.**

795 **A.** Protein sequence alignment of the regions surrounding the amino acids corresponding to
796 hAGO1 F180, G199, V254, and H751. Alignment includes hAGO1-4 and *C. elegans* ALG-1 and
797 ALG-2. The ALG-1 amino acid numbers (indicated at the bottom) correspond to *C. elegans*
798 ALG-1 isoform a (ALG-1a). Alignment is analyzed by CLUSTALW [76].

799 **B.** Domain organization of *C. elegans* ALG-1. The unstructured and non-conserved sequence at
800 the N-terminus (aa 1-187) of cel-ALG-1a is not shown.

801 **C.** hAGO2::miRNA::target complex structure (PDB:: 6MFR) with the localization of hAGO1
802 F180, G199, V254, H751 residues [31]. Side chains of the above amino acids are presented as
803 sticks.

804 **D-E.** Quantification of vulval defect phenotypes, represented by the lethality of young adult
805 hermaphrodites (**D**) and reduction in the number of progeny per animal (**E**). The lethality is
806 categorized as due to vulval integrity defect (lethality by bursting, Bst) or egg laying defect
807 (lethality by matricide, wherein embryos hatch within and consume the mother, Bag). The vulval
808 integrity defect (Bst) is considered the more severe phenotype.

809 **F.** Quantification of vulva integrity defect (left) and abnormal *col-19::gfp* expression defect (right)
810 of the *alg-1* NDD mutations with *alg-2(+)* or *alg-2(null)* genetic backgrounds.

811 **G.** Representative fluorescent images of *col-19::gfp* expression patterns for the phenotypic
812 scoring. Images showing WT *col-19::gfp* expression pattern are taken from *mals105*. Images
813 showing dim Hyp7 expression patterns are taken from *mals105; alg-1(G199S)*. Images
814 representing no Hyp7 expression pattern is taken from *mals105; alg-1(H751L)*. Scale bar is 25
815 μm .

816 **H.** Quantification of the *col-19::gfp* expression defect phenotypes.

817

818 The statistical significance of lethality and abnormal *col-19::gfp* expression are analyzed by
819 Fisher's test. The statistical significance of brood size is analyzed by Student t-test (see
820 Method). **** $p \leq 0.0001$, *** $p \leq 0.001$, ** $p \leq 0.01$, * $p \leq 0.05$.

821 **Figure 2. The C749-S750-H751 subregion is functionally critical to ALG-1.**

822 **A.** Visualization of the hAGO2 side-chains equivalent to hAGO1 C749, S750, and H751 and g5-
823 g6 nucleotides of miRNA in the AGO2::miRNA::target complex (PDB:: 6MDZ) [31]. Dashed lines
824 and numbers indicate distances between adjacent atoms (Å).

825 **B.** Lethality, brood size, and abnormal *col-19::gfp* expression phenotypes of the *alg-1(C749Y)*,
826 *alg-1(S750F)*, and *alg-1(H751L)* mutants. Phenotypes are scored at 25 °C. ****p ≤ 0.0001. ***p
827 ≤ 0.001.

828

829 **Figure 3. The *alg-1(NDD)* mutations cause allele-specific disruptions of miRNA expression
830 and miRNA associated with ALG-1.**

831 **A.** Schematic diagram of ALG-1 IP and small RNA sequencing (input).

832 **B.** Western-blotting for ALG-1 protein in input and ALG-1 immunoprecipitated samples of wild
833 type, *alg-1(null)*, and *alg-1(NDD)* mutants. Tubulin is detected as the loading control for input
834 samples.

835 **C.** Heatmap showing the levels of abundant miRNAs (≥10rpm) in the input and ALG-1 IP
836 samples of wild type and *alg-1(NDD)* mutants. Data are shown as log₂(RPM).

837 **D.** Venn diagrams showing numbers of miRNAs with statistically significant up/down-regulated
838 levels (Fold change > 2 and FDR < 0.05) in the input (top) and ALG-1 IP (bottom). Results for
839 *alg-1(V254I)* mutant are not shown because no significant perturbation was observed in ALG-
840 1(IP), while only a single miRNA was up-regulated in *alg-1(V254I)* input (Figure S3 and Table
841 S1).

842

843 **Figure 4. *alg-1* NDD mutations lead to altered guide/passenger (miR/miR*) ratios.**

844 **A.** A schematic model of ALG-1 miRNA strand loading in wild type and NDD mutant ALG-1.

845 **B-C.** Changes of miR/miR* ratio in the input (B) and ALG-1 IP (C). log₂FC miR*/miR ratio in wild
846 type vs. mutant animals (Y-axis) is plotted against miRNA abundance in wild type (X-axis).
847 Burgundy dots represent miRNAs with switched miRNA strand abundance (miR*>miR), red dots
848 represent miRNAs whose miR* strands were upregulated ≥2 fold with p≤0.05, and orange dots
849 represent miRNAs whose miR* strands were upregulated ≥2 fold but did not reach statistical
850 significance. Dashed lines, |log₂FC| = 1.

851 **D.** miRNA fold change comparison between input and ALG-1 IP. miRNAs with $|FC| > 2$ and $p <$
852 0.05 are color-coded to indicate miRNA up- or down- regulation in both input and ALG-1 IP, and
853 input or ALG-1 IP only.

854 **E.** miRNAs that exhibited reversed miRNA strand abundance in input and/or ALG-1 IP. miRNA*
855 strands are marked with an asterisk(*).

856

857 **Figure 5. *alg-1* NDD mutations lead to strong translome perturbations in *C. elegans*.**

858 **A.** Volcano plots of the ribosome protected fragments (RPF) detected in ribosome profiling of
859 NDD mutant late L4 larvae. Colored dots represent perturbed genes with statistical significance
860 ($|\log_2FC| > 1.5$, $p_{adj} < 0.1$). Also see Table S2.

861 **B.** Principal component analysis plot of translomes of the NDD mutants and *alg-1 null*. Points
862 with identical colors indicate biological replication.

863 **C.** Venn diagram for the total perturbed genes in the NDD mutants.

864 **D.** RPFs of heterochronic genes whose gain-of-function mutations were reported to cause
865 heterochronic phenotypes and have been genetically confirmed to be miRNA targets in *C.*
866 *elegans*.

867 **E.** Visualization of set1-set3 antimorphic perturbed (*amp*) genes. For each gene, the \log_2FC of
868 the *null*/WT is plotted on the x-axis and the \log_2FC of NDD mutant/WT is plotted on the y-axis.
869 Solid dots indicate perturbed genes with statistical significance ($|FC| > 1.5$, $p_{adj} < 0.1$). See
870 also Table S3.

871 **F.** Venn diagrams of set1-set3 *amp* genes in the NDD mutants.

872 **Figure 6. Antimorphic ALG-1(NDD) miRISC may sequester miRNAs into non-functional**
873 **complexes, leading to a greater miRNA loss-of-function than in the absence of ALG-1.**

874 **A.** Illustrative models of WT and NDD ALG-1 miRISC activity, with ALG-1 NDD miRISC
875 sequestering functional miRNAs away from the ALG-2 miRISC. Proposed miRISC activity is
876 shown for *alg-1* WT, *alg-1(null)*, and *alg-1(antimorphic)* genotypes.

877 **B.** Putative net repressive functionality score (NRF.score) of the most abundant miRNAs in the
878 *alg-1* NDD mutants (min.RPM > 15). Only the guide strands of miRNA were analyzed. miRNAs
879 with NRF.score < 0.5 are defined as having a *lof* NRF.score. See also Table S4.

880

881 **Figure 7. The *alg-1* NDD mutations have distinct impacts on gene target repressing modes**
882 **based on translational efficiency and mRNA abundance.**

883 **A.** Fold changes of mRNA abundance and translational efficiency (TE) of genes that are
884 significantly up-regulated and contain target sites of miRNAs with *lof* NRF.score (< 0.5). Cyan,
885 genes with significantly increased mRNA abundance ($|FC| > 1.5$, $p_{adj} < 0.1$ by *DEseq2*). Red,
886 genes with significantly increased TE ($|FC| > 1.5$, $p < 0.1$ by *Student t-test*). Magenta, genes
887 with both significantly increased TE and mRNA abundance.

888 **B.** Summary of the de-repression modes of genes that are translationally up-regulated and
889 contain target sites for miRNAs with *lof* NRF.score.

890 **C.** Distribution of the de-repression modes of the genes in (B) with significantly up-regulated TE
891 and/or significantly up-regulated mRNA abundance.

892 **D.** NRF.score of miRNAs that are down-regulated with statistical significance in both F180 Δ and
893 H751L mutants.

894 **E.** Fold changes of mRNA abundance and TE of genes that are translationally up-regulated and
895 contain target sites of miRNAs in (C).

896 **F.** Distribution of the de-repression modes of the genes in (E) with significantly up-regulated TE
897 and/or significantly up-regulated mRNA abundance

898 **G.** Fold changes of mRNA abundance and TE of genes that contain targets sites of miRNAs in
899 (C) and were simultaneously perturbed in both *alg-1*(F180 Δ) and *alg-1*(H751L) or both *alg-*
900 *1*(G199S) and *alg-1*(H751L) mutants.

901 **Figure 8. The *alg-1* NDD mutations can perturb genes with human orthologs expressed in**
902 **the brain and human orthologs related to NDD.**

903 **A.** MA plots for the translational levels of up-regulated *C. elegans* genes which have human
904 orthologs with brain translome expression. Text-labeled and colored points indicate genes that
905 are also expressed in the *C. elegans* nervous system [42]. The labels are formatted as
906 *Cel_gene_symbol* / *Hsa_gene_symbol*. See also Table S5.

907 **B.** Venn diagram for genes that are translationally up-regulated in *C.elegans* and have human
908 orthologs expressed in brain translome [42].

909 **C.** MA plots for translationally perturbed genes that have human homologs with sysNDD
910 curation [43]. Solid and text labeled dots indicate genes that contain definitive sysNDD entity.
911 Dot radius indicates the sysNDD entity counts. See also Table S5.

912

913 **Figure 9. The *alg-1* NDD mutations can trigger stress response due to proteome imbalance.**

914 **A-B.** Hypergeometric tests for enrichment of stress-related genes (A) and unfolded protein
915 response (UPR) (B) in translationally up-regulated genes in the *alg-1* NDD mutants [49, 50].

916 **C.** Summary of the possible contribution of the *alg-1/hAGO1* NDD mutations to the
917 pathogenesis of NDD.

918

919 **SUPPLEMENTAL FIGURE LEGENDS**

920 **Figure S1. Effects of homozygous and heterozygous *alg-1* NDD mutations on vulval**
921 **integrity and seam cell differentiation.**

922 **A-C.** The adult lethality (A), abnormal *col-19::gfp* (B), and numbers of progeny (C) phenotypes
923 of the homozygous (mut/mut) and heterozygous (mut/+) *alg-1* NDD mutants. Phenotypes are
924 scored at 25 °C. The statistical significance of lethality and abnormal *col-19::gfp* expression is
925 analyzed by Fisher's test. The statistical significance of brood size is analyzed by Student t-test
926 (see Method). **** $p \leq 0.0001$, *** $p \leq 0.001$.

927

928 **Figure S2 The *alg-1* NDD mutations cause allele-specific disruptions of miRNA expression**
929 **and miRNA associated with ALG-1 (part 1).**

930 **A.** (Left two columns) Volcano plots of normalized miRNA levels in the input and ALG-1 IP.
931 miRNAs with $|FC| > 2$ and $FDR < 0.05$ are color-coded as red for up-regulation or blue for down-
932 regulation. (Right column) miRNA fold changes comparison between input and ALG-1 IP and
933 the significance of the hypergeometric test of the enrichment of miRNAs that were perturbed in
934 both input and ALG-1 IP (bottom of the column).

935 **B.** Venn diagrams of miRNAs up or down-regulated with statistical significance in the *alg-*
936 *1(NDD)* and *alg-1(null)* mutants.

937 **C.** Proportions of up/down-regulation among the miRNA perturbation in input and ALG-1 IP.

938 **D.** Proportions of miRNA guide (miR) and passenger (miR*) strands among the perturbed
939 miRNAs.

940

941 **Figure S3 The *alg-1* NDD mutations cause allele-specific disruptions of miRNA expression**
942 **and/or association with ALG-1 (part 2).**

943 **A.** RPM values of major heterochronic miRNAs, whose abundance was altered in either input
944 and/or ALG-1 IP in at least one of the NDD mutants.

945 **B.** RPM values of the most abundant miRNAs with statistically significant abundance ($|FC| > 2$
946 and $p < 0.05$) changes in input and/or IP in at least one of the NDD mutants.

947

948 **Figure S4. Translatome perturbation profiles between the *alg-1* NDD mutants and the *alg-***
949 ***1 null* mutant partially overlap.**

950 **A.** Venn diagrams representing the overlap and distinction of perturbed genes between each
951 *alg-1* NDD mutant and the *alg-1 null* mutant.

952 **B-D.** Venn diagrams for the profile of set1-set3 *amp* genes (Figure 3E) in the *alg-1* NDD
953 mutants.

954 **E.** Enrichment of genes expressed in *C. elegans* vulva and seam cells in the translationally up-
955 regulated genes [41]. Enrichment analysis was tested by a hypergeometric test. ****, $p \leq 0.0001$,
956 *, $p \leq 0.05$.

957 **F.** MA plots representing the translatome of all the NDD mutants. Solid dots represent perturbed
958 genes with identical statistical significance ($|\log_2FC| > 1.5$, $p_{adj} < 0.1$).

959

960 **Figure S5. Targets of miRNAs with loss-of-function NRF.score are enriched in the**
961 **translationally up-regulated genes.**

962 **A-B.** Venn diagrams for genes translationally up-regulated in the *alg-1(NDD)* mutants and
963 genes containing target sites for miRNAs with just down-regulated levels (**A**) and with a *lof*
964 NRF.score (**B**).

965 **C.** Significance of hypergeometric test for the enrichment of the targets for miRNAs with
966 decreased expression levels and the targets miRNAs with *lof*. NRF.score in the translationally
967 up-regulated genes.

968

969 **Figure S6. The NDD mutations can perturb the expression of miRNA target genes that have**
970 **human orthologs with brain expression.**

971 **A.** MA plots for the translational levels of up-regulated *C. elegans* genes which have human
972 orthologs with brain translatome expression. Text-labeled and colored points indicate genes that
973 contain target sites of miRNAs with *lof* NRF.score in *C.elegans*. The labels are formatted as
974 Cel_gene_symbol / Hsa_gene_symbol.

975 **B.** Venn diagram for *lof* miRNA (NRF.score < 0.5) target genes that are translationally up-
976 regulated in *C.elegans* and have human ortholog expressed in brain translatome.

977

978 **Figure S7. Translational perturbation of stress responses-related genes in the *alg-1* NDD**
979 **mutant animals.**

980 **A.** MA plot of the translational levels of all protein-coding genes. Solid and text-labeled dots
981 represent genes that are related to stress response [50].

982 **B-C.** Translational levels of small heat shock protein orthologous genes (**B**) and HSP70/HSP90
983 orthologous genes (**C**) in the NDD mutants and *null* mutants [48].

984 **D.** RPF levels of the proteasome component proteins and proteolysis-related proteins [77].
985 Significance tested by DESeq2. ***, $p \leq 0.001$; *, $p \leq 0.05$.

986

987 **Figure S8. The F180 and G199S may disrupt the function associated with the L1 β -hairpin.**

988 **A.** Visualization of the L1 β -hairpin (brown) in the *hAGO2::miRNA::target* complex (PDB::
989 6MDZ) [31]. Target RNA is colored blue and miRNA is colored red.

990 **B.** Simplified structure of *hAGO2* L1 domain and miRNA::target duplex. L1 β -hairpin is colored
991 in magenta, with F180 and G199 highlighted in red.

992

993 **SUPPLEMENTAL TABLES**

994 **Table S1. Differential expression analyses of total and top changed miRNAs in the *alg-1***
995 **NDD mutants.** (Related to Figure 3, S2, S3)

996 **Table S2. Differential expression analyses of ribosome profiling, RNAseq, and translation**
997 **efficiency (TE) of the *alg-1* NDD mutants and analysis of the repressing modes.** (Related
998 to Figure 5, 7, S4)

999 **Table S3. Lists of antimorphic perturbed (*amp*) genes in the *alg-1* NDD mutants.** (Related
1000 to Figure 5, S4)

1001 **Table S4. The net repressive functionality scores (NRF.score) of miRNAs in the *alg-1***
1002 **NDD mutants.**

1003 Only miRNAs with a minimum 15 RPM were analyzed. (Related to Figure 6, S5)

1004 **Table S5. Lists of nervous system-related genes and their differential expression**
1005 **analyses of the translational levels in the *alg-1* NDD mutant.**

1006 **A.** Translationally perturbed *C. elegans* genes with orthologs expressed in human brains
1007 translome. **B.** Lists of *C.elegans*/human homologs that were translationally up-regulated in
1008 *alg-1* NDD mutants and are related to NDD in sysNDD database (updated to 2.28.2023) [43].
1009 (Related to Figure 8, S6).

1010 **Table S6. Key oligonucleotides used in this paper for CRISPR/Cas9 mutagenesis.**

1011 **Table S7. *C. elegans* strains used in this paper.**

Table S6. Key oligonucleotides used in this paper for CRISPR/Cas9 mutagenesis.

30mer_RPF_marker_RNA rArCrUrArGrCrCrUrUrArUrUrUrArArCrUrUrGrCrUrArUrGrCrUrCrUrA	IDT	N/A
Alt-R <i>alg-1</i> F180 crRNA: CCAGAAGCATTAGGAAGTGG + Alt-R	IDT	AltR_Cas-9_crRNA_alg-1_F180
Alt-R <i>alg-1</i> G199 crRNA: GGTGGCCGTGAAGTCTGGTT + Alt-R	IDT	AltR_Cas-9_crRNA_alg-1_G199
Alt-R <i>alg-1</i> V254 crRNA1: TCAACGTGTCAAGTTCACCA + Alt-R	IDT	hAGO1_V254I_g2
Alt-R <i>alg-1</i> V254 crRNA2: TTTGAGACCACGAATTCCT + Alt-R	IDT	hAGO1_V254I_g5
Alt-R <i>alg-1</i> H751 crRNA1: GCACAAGTAGAAGTCAAAC + Alt-R	IDT	hAGO1_H751L_g2
Alt-R <i>alg-1</i> H751 crRNA2: AGAAGTCAAACCTCGGTTGGG + Alt-R	IDT	hAGO1_H751L_g3
Alt-R <i>alg-1</i> C749 crRNA1: TTCTACTTGTGCTCTCATGC+ Alt-R	IDT	AltR_Cas-9_crRNA_alg-1_C749
Alt-R <i>dpy-10</i> crRNA as co-CRISPR marker: CTACCATAGGCACCACGAG + Alt-R	IDT	AltR_Cas-9_crRNA_dpy-10_cn64
Alt-R CRISPR-Cas-9 tracrRNA	IDT	Cat# 1072533
F180del ssDNA donor: ATGGATGTCATTCTTCGTCATCTTCCAAGCTTGAAATACACTCCTG TCGGACGTTTATTCTCGCCACCAGTTTCTAATGCTTCTGGAGTCAT GGCAGGATCATGCCCTCCCCAGGCT	IDT	F180del_ssDNA_donor
G199S ssDNA donor: CACTCCGCTGGACAATATCACGCCGAGAGCAAACCTCGGGGTGG CCGTGAAGTCTGGTTTTCTTCCATCAGTCGGTTCGCCATCTCAG TGGAAAATGATGCTTAACATTGATGTCTCT	IDT	G199S_ssDNA_donor
V254I ssDNA donor: GTCCACAGTGGGTGATTTCAATTTTGGAGACCACGAATTTCTTTAGT GAACTTGATACGTTGAGCATCAGATAGAGCACGACGCTCAGCAAG AGCTTGAAC	IDT	hAGO1_V254I_donor
H751L ssDNA donor: CCGCCAGGAAGTGTGCGATGTAGGAATTAACCCCAACTGAG TTTGACTTCTACTTGTGCTCTTGTCTGGTATTCAAGGAACATCTC GTCCATCCCATTACCATGTTCTTTGGGA	IDT	hAGO1_H751L_donor
C749Y ssDNA donor: AAAGCATACAATATCCGCCAGGAAGTGTGCGATGTAGGAATTA CCCACCAACCGAGTTTACTTCTACTTGTACTCTCATGCTGGTAT TCAAGGAACATCTCGTCCATCCCATTACCATGTTCTTTGGGATGAC ACAATCTGA	IDT	C749Y_ssDNA_donor
F180/G199 genotyping forward primer: GGATTTGATGTCACACTTCTGG	IDT	alg-1_SEQ_F5
F180/G199 genotyping reverse primer: CATCAGATAGAGCACGACGCTC	IDT	alg-1_SEQ_R5
V genotyping forward primer: GGATTTGATGTCACACTTCTGG	IDT	alg-1_SEQ_F5
F180/G199 genotyping reverse primer: CATCAGATAGAGCACGACGCTC	IDT	alg-1_SEQ_R5
V254I genotyping forward primer: CATTGATGTCTCTGCGACTGC	IDT	AGO1_v254I.for1
V254I genotyping reverse primer: CACTCAATAGTTTGACCAGTCTCC	IDT	AGO1_v254I.rev1
H751/C749 genotyping forward primer: GGCTTGCATGATGCTTGAAG	IDT	AGO1_h751I.for1
H751/C749 genotyping reverse primer: GTGCATCTGACGTAGGTATGG	IDT	AGO1_h751I.rev1
ASO for rRNA/srpR depletion:		https://en.bio-protocol.org/prep614

Table S7. *C. elegans* strains

Strain name	Genotype
N2	WT
VT1367	<i>mals105</i>
VT1274	<i>alg-2(ok304, 0); mals105</i>
VT3841	<i>alg-1(tm492, 0)</i>
VT2325	<i>mals105; alg-1(tm492,0)</i>
VT3824	<i>alg-1(ma447,F180del)</i>
VT3809	<i>alg-1(ma443, G199S)</i>
UY98	<i>alg-1(zen25, V254I)</i>
UY84	<i>alg-1(zen18,H751L)</i>
VT3823	<i>mals105; alg-1(ma447,F180del)</i>
VT3805	<i>mals105; alg-1(ma443, G199S)</i>
UY104	<i>mals105; alg-1(zen25, V254I)</i>
UY99	<i>mals105; alg-1(zen18,H751L)</i>
VT4270	<i>mals105; alg-1(ma470,C749Y)</i>
VT1997	<i>mals105; alg-1(ma192, S750F)</i>
VT3520	<i>alg-2(ok304); ieSi57; mals105; alg-1(ma349, degron)</i>
UY152	<i>alg-2(ok304); mals105; alg-1(zen18, H751L); mnDp3(umnlis26)</i>
VT3842	<i>alg-2(ok304); mals105; alg-1(ma447,F180del); mnDp3(umnlis26)</i>
VT3832	<i>alg-2(ok304); mals105; alg-1(ma443, G199S)</i>
UY126	<i>alg-2(ok304); mals105; alg-1(zen25, V254I)</i>

REFERENCE

- 1012 1. Ambros, V., *The functions of animal microRNAs*. Nature, 2004. **431**(7006): p. 350-5.
- 1013 2. Bartel, D.P., *Metazoan MicroRNAs*. Cell, 2018. **173**(1): p. 20-51.
- 1014 3. Lee, R.C., R.L. Feinbaum, and V. Ambros, *The C. elegans heterochronic gene lin-4 encodes small*
- 1015 *RNAs with antisense complementarity to lin-14*. Cell, 1993. **75**(5): p. 843-54.
- 1016 4. Lee, Y., et al., *The nuclear RNase III Drosha initiates microRNA processing*. Nature, 2003.
- 1017 **425**(6956): p. 415-9.
- 1018 5. Iwakawa, H.O. and Y. Tomari, *The Functions of MicroRNAs: mRNA Decay and Translational*
- 1019 *Repression*. Trends Cell Biol, 2015. **25**(11): p. 651-665.
- 1020 6. Meister, G., *Argonaute proteins: functional insights and emerging roles*. Nat Rev Genet, 2013. **14**(7):
- 1021 p. 447-59.
- 1022 7. Grishok, A., et al., *Genes and mechanisms related to RNA interference regulate expression of the*
- 1023 *small temporal RNAs that control C. elegans developmental timing*. Cell, 2001. **106**(1): p. 23-34.
- 1024 8. Bouasker, S. and M.J. Simard, *The slicing activity of miRNA-specific Argonautes is essential for*
- 1025 *the miRNA pathway in C. elegans*. Nucleic Acids Res, 2012. **40**(20): p. 10452-62.
- 1026 9. Eulalio, A., E. Huntzinger, and E. Izaurralde, *GW182 interaction with Argonaute is essential for*
- 1027 *miRNA-mediated translational repression and mRNA decay*. Nat Struct Mol Biol, 2008. **15**(4): p.
- 1028 346-53.
- 1029 10. Dueck, A., et al., *microRNAs associated with the different human Argonaute proteins*. Nucleic Acids
- 1030 Res, 2012. **40**(19): p. 9850-62.
- 1031 11. Muller, M., F. Fazi, and C. Ciaudo, *Argonaute Proteins: From Structure to Function in Development*
- 1032 *and Pathological Cell Fate Determination*. Front Cell Dev Biol, 2019. **7**: p. 360.
- 1033 12. Zinovyeva, A.Y., et al., *Mutations in Conserved Residues of the C. elegans microRNA Argonaute*
- 1034 *ALG-1 Identify Separable Functions in ALG-1 miRISC Loading and Target Repression*. PLoS
- 1035 Genet, 2014. **10**(4): p. e1004286.
- 1036 13. Feng, B., et al., *Increased argonaute 2 expression in gliomas and its association with tumor*
- 1037 *progression and poor prognosis*. Asian Pacific Journal of Cancer Prevention, 2014. **15**(9): p. 4079-
- 1038 4083.
- 1039 14. Gou, L.T., et al., *Ubiquitination-Deficient Mutations in Human Piwi Cause Male Infertility by*
- 1040 *Impairing Histone-to-Protamine Exchange during Spermiogenesis*. (1097-4172 (Electronic)).
- 1041 15. Zhang, J., et al., *Up-regulation of Ago2 expression in gastric carcinoma*. Medical Oncology, 2013.
- 1042 **30**(3): p. 628.
- 1043 16. Völler, D., et al., *Argonaute Family Protein Expression in Normal Tissue and Cancer Entities*. (1932-
- 1044 6203 (Electronic)).
- 1045 17. Wu, J., et al., *Argonaute proteins: Structural features, functions and emerging roles*. J Adv Res,
- 1046 2020. **24**: p. 317-324.
- 1047 18. Tokita, M.J., et al., *Five children with deletions of 1p34.3 encompassing AGO1 and AGO3*. Eur J
- 1048 Hum Genet, 2015. **23**(6): p. 761-5.
- 1049 19. Jacher, J.E. and J.W. Innis, *Interstitial microdeletion of the 1p34.3p34.2 region*. Mol Genet Genomic
- 1050 Med, 2018.
- 1051 20. Schalk, A., et al., *De novo coding variants in the AGO1 gene cause a neurodevelopmental disorder*
- 1052 *with intellectual disability*. J Med Genet, 2021.
- 1053 21. Lessel, D., et al., *Germline AGO2 mutations impair RNA interference and human neurological*
- 1054 *development*. Nat Commun, 2020. **11**(1): p. 5797.
- 1055 22. Takagi, M., et al., *Complex congenital cardiovascular anomaly in a patient with AGO1-associated*
- 1056 *disorder*. Am J Med Genet A, 2022.
- 1057 23. Meister, G., et al., *Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs*.
- 1058 Mol Cell, 2004. **15**(2): p. 185-97.


- 1059 24. Sulston, J.E., et al., *The embryonic cell lineage of the nematode Caenorhabditis elegans*. Dev Biol, 1983. **100**(1): p. 64-119.
- 1060
- 1061 25. Ren, Z. and V.R. Ambros, *Caenorhabditis elegans microRNAs of the let-7 family act in innate immune response circuits and confer robust developmental timing against pathogen stress*. Proc Natl Acad Sci U S A, 2015. **112**(18): p. E2366-75.
- 1062
- 1063
- 1064 26. Ilbay, O. and V. Ambros, *Regulation of nuclear-cytoplasmic partitioning by the lin-28-lin-46 pathway reinforces microRNA repression of HBL-1 to confer robust cell-fate progression in C. elegans*. Development, 2019. **146**(21).
- 1065
- 1066
- 1067 27. Reinhart, B.J., et al., *The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans*. Nature, 2000. **403**(6772): p. 901-6.
- 1068
- 1069 28. Abbott, A.L., et al., *The let-7 MicroRNA family members mir-48, mir-84, and mir-241 function together to regulate developmental timing in Caenorhabditis elegans*. Dev Cell, 2005. **9**(3): p. 403-14.
- 1070
- 1071
- 1072 29. Zinovyeva, A.Y., et al., *Caenorhabditis elegans ALG-1 antimorphic mutations uncover functions for Argonaute in microRNA guide strand selection and passenger strand disposal*. Proc Natl Acad Sci U S A, 2015. **112**(38): p. E5271-80.
- 1073
- 1074
- 1075 30. Schirle, N.T., J. Sheu-Gruttadauria, and I.J. MacRae, *Structural basis for microRNA targeting*. Science, 2014. **346**(6209): p. 608-13.
- 1076
- 1077 31. Sheu-Gruttadauria, J., et al., *Beyond the seed: structural basis for supplementary microRNA targeting by human Argonaute2*. EMBO J, 2019.
- 1078
- 1079 32. Schirle, N.T. and I.J. MacRae, *The crystal structure of human Argonaute2*. Science, 2012. **336**(6084): p. 1037-40.
- 1080
- 1081 33. Bazzini, A.A., M.T. Lee, and A.J. Giraldez, *Ribosome profiling shows that miR-430 reduces translation before causing mRNA decay in zebrafish*. Science, 2012. **336**(6078): p. 233-7.
- 1082
- 1083 34. Ingolia, N.T., *Ribosome Footprint Profiling of Translation throughout the Genome*. Cell, 2016. **165**(1): p. 22-33.
- 1084
- 1085 35. Moss, E.G., R.C. Lee, and V. Ambros, *The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA*. Cell, 1997. **88**(5): p. 637-46.
- 1086
- 1087 36. Slack, F.J., et al., *The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor*. Mol Cell, 2000. **5**(4): p. 659-69.
- 1088
- 1089 37. Abrahante, J.E., et al., *The Caenorhabditis elegans hunchback-like gene lin-57/hbl-1 controls developmental time and is regulated by microRNAs*. Dev Cell, 2003. **4**(5): p. 625-37.
- 1090
- 1091 38. Duan, Y., I. Veksler-Lublinsky, and V. Ambros, *Critical contribution of 3' non-seed base pairing to the in vivo function of the evolutionarily conserved let-7a microRNA*. Cell Rep, 2022. **39**(4): p. 110745.
- 1092
- 1093
- 1094 39. Giraldez, A.J., et al., *Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs*. Science, 2006. **312**(5770): p. 75-9.
- 1095
- 1096 40. Duan, Y., Y. Sun, and V. Ambros, *RNA-seq with RNase H-based ribosomal RNA depletion specifically designed for C. elegans*. MicroPubl Biol, 2020. **2020**.
- 1097
- 1098 41. Consortium, T.A.o.G.R., *Alliance of Genome Resources Portal: unified model organism research platform*. Nucleic Acids Research, 2019. **48**(D1): p. D650-D658.
- 1099
- 1100 42. Duffy, E.E., et al., *Developmental dynamics of RNA translation in the human brain*. Nat Neurosci, 2022. **25**(10): p. 1353-1365.
- 1101
- 1102 43. Kochinke, K., et al., *Systematic Phenomics Analysis Deconvolutes Genes Mutated in Intellectual Disability into Biologically Coherent Modules*. Am J Hum Genet, 2016. **98**(1): p. 149-64.
- 1103
- 1104 44. Balch, W.E., et al., *Adapting proteostasis for disease intervention*. Science, 2008. **319**(5865): p. 916-9.
- 1105
- 1106 45. Hartl, F.U., A. Bracher, and M. Hayer-Hartl, *Molecular chaperones in protein folding and proteostasis*. Nature, 2011. **475**(7356): p. 324-32.
- 1107

- 1108 46. Taylor, R.C., K.M. Berendzen, and A. Dillin, *Systemic stress signalling: understanding the cell non-*
1109 *autonomous control of proteostasis*. Nature reviews Molecular cell biology, 2014. **15**(3): p. 211-217.
- 1110 47. Hetz, C., E. Chevet, and S.A. Oakes, *Proteostasis control by the unfolded protein response*. Nature
1111 cell biology, 2015. **17**(7): p. 829-838.
- 1112 48. Walther, D.M., et al., *Widespread Proteome Remodeling and Aggregation in Aging C. elegans*. Cell,
1113 2015. **161**(4): p. 919-32.
- 1114 49. Holdorf, A.D., et al., *WormCat: An Online Tool for Annotation and Visualization of Caenorhabditis*
1115 *elegans Genome-Scale Data*. Genetics, 2020. **214**(2): p. 279-294.
- 1116 50. Higgins, D.P., et al., *Defining characteristics and conservation of poorly annotated genes in*
1117 *Caenorhabditis elegans using WormCat 2.0*. Genetics, 2022. **221**(4).
- 1118 51. Haslbeck, M., et al., *Some like it hot: the structure and function of small heat-shock proteins*. (1545-
1119 9993 (Print)).
- 1120 52. Hu, C., et al., *Heat shock proteins: Biological functions, pathological roles, and therapeutic*
1121 *opportunities*. MedComm (2020), 2022. **3**(3): p. e161.
- 1122 53. Iwasaki, S., et al., *Hsc70/Hsp90 chaperone machinery mediates ATP-dependent RISC loading of*
1123 *small RNA duplexes*. Mol Cell, 2010. **39**(2): p. 292-9.
- 1124 54. Hutvagner, G. and M.J. Simard, *Argonaute proteins: key players in RNA silencing*. Nat Rev Mol
1125 Cell Biol, 2008. **9**(1): p. 22-32.
- 1126 55. Jinek, M. and J.A. Doudna, *A three-dimensional view of the molecular machinery of RNA*
1127 *interference*. Nature, 2009. **457**(7228): p. 405-12.
- 1128 56. Song, J.J., et al., *Crystal structure of Argonaute and its implications for RISC slicer activity*. Science,
1129 2004. **305**(5689): p. 1434-7.
- 1130 57. Rivas, F.V., et al., *Purified Argonaute2 and an siRNA form recombinant human RISC*. Nat Struct
1131 Mol Biol, 2005. **12**(4): p. 340-9.
- 1132 58. Xiao, Y., et al., *Structural basis for RNA slicing by a plant Argonaute*. bioRxiv, 2022: p.
1133 2022.07.15.500266.
- 1134 59. McGeary, S.E., et al., *MicroRNA 3'-compensatory pairing occurs through two binding modes, with*
1135 *affinity shaped by nucleotide identity and position*. Elife, 2022. **11**.
- 1136 60. Dore, L.C., et al., *A GATA-1-regulated microRNA locus essential for erythropoiesis*. Proc Natl Acad
1137 Sci U S A, 2008. **105**(9): p. 3333-8.
- 1138 61. Yang, J.S., et al., *Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-*
1139 *mediated microRNA biogenesis*. Proc Natl Acad Sci U S A, 2010. **107**(34): p. 15163-8.
- 1140 62. Parenti, I., et al., *Neurodevelopmental Disorders: From Genetics to Functional Pathways*. Trends
1141 Neurosci, 2020. **43**(8): p. 608-621.
- 1142 63. Höhn, A., A. Tramutola, and R. Cascella, *Proteostasis failure in neurodegenerative diseases: focus*
1143 *on oxidative stress*. Oxidative medicine and cellular longevity, 2020. **2020**.
- 1144 64. Arribere, J.A., et al., *Efficient Marker-Free Recovery of Custom Genetic Modifications with*
1145 *CRISPR/Cas9 in Caenorhabditis elegans*. Genetics, 2014. **198**(3): p. 837-46.
- 1146 65. Schwartz, M.L., et al., *High-efficiency CRISPR gene editing in C. elegans using Cas9 integrated*
1147 *into the genome*. PLoS Genet, 2021. **17**(11): p. e1009755.
- 1148 66. Schindelin, J., et al., *Fiji: an open-source platform for biological-image analysis*. Nat Methods, 2012.
1149 **9**(7): p. 676-82.
- 1150 67. Li, L. and A.Y. Zinovyeva, *Protein Extract Preparation and Co-immunoprecipitation from*
1151 *Caenorhabditis elegans*. J Vis Exp, 2020(159).
- 1152 68. Zou, Y., et al., *Developmental decline in neuronal regeneration by the progressive change of two*
1153 *intrinsic timers*. Science, 2013. **340**(6130): p. 372-376.
- 1154 69. Gu, W., et al., *Cloning Argonaute-associated small RNAs from Caenorhabditis elegans*. Methods
1155 Mol Biol, 2011. **725**: p. 251-80.


- 1156 70. Langmead, B. and S.L. Salzberg, *Fast gapped-read alignment with Bowtie 2*. Nat Methods, 2012.
1157 **9**(4): p. 357-9.
- 1158 71. Langmead, B., et al., *Ultrafast and memory-efficient alignment of short DNA sequences to the*
1159 *human genome*. Genome Biol, 2009. **10**(3): p. R25.
- 1160 72. Friedlander, M.R., et al., *miRDeep2 accurately identifies known and hundreds of novel microRNA*
1161 *genes in seven animal clades*. Nucleic Acids Res, 2012. **40**(1): p. 37-52.
- 1162 73. Anders, S. and W. Huber, *Differential expression analysis for sequence count data*. Genome Biol,
1163 2010. **11**(10): p. R106.
- 1164 74. Agarwal, V., et al., *Predicting effective microRNA target sites in mammalian mRNAs*. Elife, 2015.
1165 **4**.
- 1166 75. Harris, T.W., et al., *WormBase: a modern Model Organism Information Resource*. Nucleic Acids
1167 Res, 2020. **48**(D1): p. D762-D767.
- 1168 76. Thompson, J.D., T.J. Higgins Dg Fau - Gibson, and T.J. Gibson, *CLUSTAL W: improving the*
1169 *sensitivity of progressive multiple sequence alignment through sequence weighting, position-*
1170 *specific gap penalties and weight matrix choice*. (0305-1048 (Print)).
- 1171 77. Papaevgeniou, N. and N. Chondrogianni, *The ubiquitin proteasome system in Caenorhabditis*
1172 *elegans and its regulation*. Redox Biol, 2014. **2**: p. 333-47.

Figure 1


A




B




C




D




E



G



F



H





Figure 2

A



B




Figure 3




Figure 4






Figure 5


A




B




C



D



E



F




Figure 6





Figure 7




Figure 8










Figure 9










A



B







C

- p (targets of miRNA with *lof* NRF-score)
- △ p (targets of miRNA with down-regulated levels)






Figure S6



A



B

